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Amyloid beta (Aβ) is the major component of the extracellular senile plaque, a 
pathological hallmark seen in the brain of Alzheimer’s disease (AD) patients, 
and gives a toxic edge to neuron in several ways. Some membrane proteins have 
been suggested to be Aβ receptors sine they bind to soluble Aβ and trigger 
neurotoxic pathway. Fc-receptor IIb (FcγRIIb) serves as a receptor for soluble 
Aβ oligomer. Genetic deletion of FcγRIIb ameliorates neuronal death and LTP 
impairment induced by Aβ oligomer and rescues memory deficits seen in 
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PDAPP AD mouse model. Recently, it is reported that alteration of 
phosphoinositide metabolism elicited by Aβ-FcγRIIb interaction is responsible 
for the hyperphosphorylation of tau and memory impairment in 3x Tg-AD 
mouse model. Here, I demonstrate another mechanistic study supporting the 
pathogenic role of FcγRIIb in AD through neuronal internalization of Aβ. In 
addition, I identify the role of Lyn in mediating phosphorylation of FcγRIIb 
under Aβ exposure and propose the protective effect of a putative Lyn inhibitor 
isolated by virtual screening.  
Intraneuronal Aβ is characterized in the brain of early-phase AD 
patients. Some AD mouse models with intensive intraneuronal Aβ even 
manifest memory loss without extracellular amyloid deposits. Further, the 
propagation of pathogenic Aβ between neurons is linked to accumulation of Aβ 
in neuron. However, molecular mediator to be in charge of neuronal Aβ 
accumulation and its propagation to adjacent neuron is unclear. In chapter I, I 
demonstrate the role of FcγRIIb2 variant in neuronal uptake and interneuronal 
spreading of pathogenic Aβ. Neuronal uptake of oligomeric Aβ1-42 was reduced 
in Fcgr2b knockout neurons compared to WT neuron. In 3x Tg-AD mouse 
model, both intraneuronal and soluble Aβ1-42 were diminished by loss-of-
function of FcγRIIb. Moreover, memory deficits were alleviated by forebrain-
specific expression of Aβ-uptake-defective Fcgr2b mutant in 3xTg-AD mice. I 
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also found that enriched expression of transcription variant 2 of FcγRIIb 
(FcγRIIb2) in neuron is associated with elevated uptake of Aβ. Target of Myb1 
(TOM1) isolated from functional screening bind to FcγRIIb2 and suppress 
FcγRIIb2-mediated Aβ internalization. Accelerated uptake of Aβ via FcγRIIb2 
leads to cytoplasmic and mitochondrial accumulation of Aβ over endocytic 
compartments and causes neurotoxicity. Finally, blockade of propagation of 
intraneuronal Aβ to connected neuron by Fcgr2b KO is analyzed by using 
microfluidic devices. To sum up, I demonstrate a novel function of FcγRIIb2 
variant in the pathogenesis of AD by regulating intraneuronal Aβ.  
Lyn is originally considered to be a member of Src-family tyrosine 
kinase and take a role in inhibiting immune cells to phosphorylate immune 
complex binding proteins, including FcγRIIb. However, its association to Aβ-
FcγRIIb signaling in neuron is uncertain. In Chapter II, I demonstrate that Lyn 
is critical for Aβ1-42-mediated neurotoxicity by phosphorylating FcγRIIb. Aβ1-42 
oligomer activated Lyn and further induced the tyrosine phosphorylation of 
FcγRIIb in neuronal cells. Interestingly, both Aβ1-42-initiated FcγRIIb 
phosphorylation and cell death were reduced by knockdown of Lyn in neuronal 
cells. A small molecule KICG2576, a putative ATP-competitive inhibitor of Lyn 
was isolated from virtual screening. Binding of KICG2576 to the cleft between 
the two lobes of Lyn kinase domain was verified by co-crystal structure. 
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Whereas Aβ-induced FcγRIIb phosphorylation was attenuated by KICG2576, 
Aβ- or FcγRIIb-induced neuronal cell death were also suppressed. Aβ1-42-
induced memory impairment determined by Y-maze and novel object 
recognition tests were also diminished by intracerebroventricularly injected 
KICG2675. Finally, I confirmed the activation of Lyn in the brain of AD patients 
compared to non-AD controls. Taken together, Lyn plays an essential role in 
Aβ–mediated neurotoxicity, providing detailed understanding of Aβ- FcγRIIb 
neurotoxic pathway in AD pathogenesis.  
 
Key Words: Alzheimer’s disease, Amyloid beta, Intraneuronal Aβ, Propagation 
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Aberrant role of FcγRIIb2 variant 
in the propagation and pathogenesis of 





Intraneuronal Aβ accumulation correlates with the onset of Alzheimer’s disease 
(AD) and is potentially linked to the propagation of pathogenic Aβ through 
neurons. However, critical mediator associated with AD pathology needs to be 
clarified. Here, I report that FcγRIIb2 variant functions in neuronal uptake and 
interneuronal spreading of pathogenic Aβ. Accumulation of oligomeric Aβ1-42, 
not monomeric Aβ1-42 or oligomeric Aβ1-40, was blocked by Fcgr2b knockout 
in neurons. Aβ1-42 internalization was dependent on the di-leucine motif of 
FcγRIIb2 and attenuated by TOM1, a FcγRIIb2-binding protein. Cytosolic 
accumulation of Aβ, including mitochondria, via endocytic compartments 
caused neurotoxicity. Moreover, neuronal accumulation of Aβ and memory 
deficits were simultaneously ameliorated by interfering Aβ-FcγRIIb2 
interaction and by forebrain-specific expression of Aβ-uptake-defective Fcgr2b 
mutant in 3xTg-AD mice. In addition, Aβ propagation to connected neurons 
occurs through FcγRIIb2. Our findings reveal a novel role of FcγRIIb2 





Alzheimer’s disease (AD) is the most frequent type of senile dementia with 
symptoms of cognitive decline and memory loss. Accumulation of amyloid-β 
(Aβ) in the forebrain is the most prominent feature of AD, and Aβ production 
is accelerated by familial AD mutations in amyloid-β precursor protein (APP) 
and presenilin 1 and 2 genes (Querfurth and LaFerla, 2010). Although the 
extracellular amyloid deposition mainly composed of Aβ was regarded as the 
key feature of AD in the past, mounting evidences have shown that 
intraneuronal Aβ plays a key role in neurotoxicity. The presence of 
intraneuronal Aβ precedes the build-up of extracellular amyloid plaques in 
individuals with mild cognitive impairment and AD (LaFerla et al., 2007). In 
many AD mouse models, intraneuronal Aβ strongly correlates with the onset of 
memory impairment, sometimes even without extracellular Aβ load (Billings et 
al., 2005; Eimer and Vassar, 2013; Tomiyama et al., 2010). Moreover, AD-like 
neuronal defects are ameliorated by the modulation of intraneuronal Aβ-
degrading enzymes, such as neprilysin, endothelin-converting enzymes, and 
nuclear inclusion a (NIa) (Marr et al., 2003; Pacheco-Quinto and Eckman, 2013; 
Shin et al., 2014).  
Aβ is generated by a sequential cleavage of APP by β-secretase 1 and γ-
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secretase complex along the endocytic pathway (Haass et al., 2012). Most 
cleaved Aβ in the lumen of endocytic compartments is secreted extracellularly 
and this event is regulated by neuronal activity (Cirrito et al., 2008; Moghekar 
et al., 2011; Tampellini et al., 2009). Thus, a substantial portion of intraneuronal 
Aβ is from the re-uptake of secreted Aβ. Receptor for advanced glycation 
endproduct (RAGE) and low-density lipoprotein receptor-related protein 1 
(LRP1) were reported to mediate neuronal uptake of Aβ (Kanekiyo and Bu, 
2014; Takuma et al., 2009). However, pathologic impact of RAGE is 
controversial and is not shown in in vivo model (Vodopivec et al., 2009). In 
addition, internalized Aβ through LRP1 is linked to the clearance pathway rather 
than the formation of intraneuronal Aβ pool (Kanekiyo et al., 2013). Thus, there 
is a discrepancy in understanding the deleterious role of intraneuronal Aβ with 
the current view on Aβ receptors.  
Cell-to-cell propagation of misfolded proteins is a common feature over 
many neurodegenerative diseases (Guo and Lee, 2014). In the case of Aβ, the 
amyloid deposition extends from the site of exogenous Aβ graft in AD mouse 
models (Meyer-Luehmann et al., 2006; Ye et al., 2015). Moreover, spreading of 
Aβ between neurons is accompanied by synaptic dysfunction and neurotoxicity 
(Domert et al., 2014; Harris et al., 2010). While endocytic pathway may 
function in interneuronal propagation of Aβ, inhibiting cellular prion protein, 
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NMDA receptor, or AMPA receptor does not affect Aβ propagation (Nath et 
al., 2012). Thus, critical mediator responsible for Aβ uptake for neurotoxicity 
and neuronal transmission is unknown yet. Role of Fc-receptor IIb (FcγRIIb) 
as a Aβ receptor was previously discovered (Kam et al., 2013). While FcγRIIb 
deficiency ameliorates memory deficits in PDAPP AD mice, the precise manner 
of neurotoxicity induced by FcγRIIb-Aβ interaction remains to be solved. Here, 
I determined that the neuronal FcγRIIb2 variant is critical in neuronal uptake of 





FcγRIIb is an essential receptor for neuronal uptake of Aβ1-42 oligomers  
To quantify intracellular Aβ, I used a subcellular fractionation assay after 
extracellular Aβ treatment to primary neurons. Consistent with the previous 
studies (LaFerla et al., 2007; Takuma et al., 2009), Aβ was found largely in the 
membrane-enclosing organelles, including endocytic compartments, as well as 
in the cytoplasm and mitochondria (Figure I-1A). Then, monomeric Aβ1-42 
(mAβ1-42) and oligomeric Aβ1-42 (oAβ1-42) were prepared and assessed for their 
internalization into primary neurons and astrocytes (Figure I-1B). Interestingly, 
oAβ1-42 was preferentially internalized into primary neurons, while mAβ1-42 was 
internalized by primary astrocytes. Consistent with this observation, confocal 
microscopy showed that FITC-oAβ1-42 and FITC-mAβ1-42 were found mainly 
inside primary neurons and astrocytes, respectively, when cells were incubated 
with FITC-labeled Aβ1-42 (Figure I-2). These results illustrate that oAβ1-42 is 
preferentially internalized into primary neurons relative to mAβ1-42.  
I then evaluated the relevance of FcγRIIb function in cellular uptake of Aβ 
species because of the previous report showing that FcγRIIb acts as a receptor 
for oAβ1-42 in the AD brains (Kam et al., 2013). The results revealed that oAβ1-
42 was internalized into WT cortical neurons but not into Fcgr2b KO cortical 
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neurons (Figure I-3A). Similar pattern and level of oAβ1-42 uptake were also 
observed in WT and Fcgr2b KO astrocytes. Compared to oAβ1-42, however, 
mAβ1-42 uptake was predominant in primary astrocytes and was not much 
affected by Fcgr2b KO. Consistently, FITC-oAβ1-42 internalization was also 
declined by Fcgr2b KO in MAP2b-positive hippocampal neurons, whereas 
FITC-mAβ1-42 was not significantly internalized (Figures I-3B and C). 
Comparison of the kinetics revealed that oAβ1-42 uptake over time was delayed 
by Fcgr2b KO in neurons (Figure I-4); internalized Aβ was detected at 1.5 h 
after treatment in WT neurons and at 12 h in Fcgr2b KO neurons. Moreover, 
among Aβ species, oligomeric Aβ1-40 (oAβ1-40) was not internalized into primary 
neurons compared to oAβ1-42 (Figure I-5A). Furthermore, by utilizing the 
conditioned media of 7PA2 cells which secrete soluble Aβ oligomers (Walsh et 
al., 2002), I found that FcγRIIb could internalize Aβ1-42, but not Aβ1-40 (Figures 
I-5B and C). The results suggest that FcγRIIb is crucial for neuronal uptake of 
oAβ1-42 over mAβ1-42 or oAβ1-40.  
In addition, neuronal uptake of Aβ was blocked by addition of purified 
FcγRIIb extracellular domain (FcγRIIb-ED) to the culture medium (Figure I-
6A). Furthermore, Aβ internalization was enhanced by the overexpression of 
FcγRIIb or FcγRIIb Ig1 mutant, but not by deletion mutant of FcγRIIb Ig2 
domain which was reported to be critical for the interaction with oAβ1-42 (Kam 
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et al., 2013) (Figure I-6B). I thus conducted a virtual screening based on the 
Aβ1-42 N-terminal stretch that was reported to be important for binding of 
FcγRIIb to the Ig2 domain (Kam et al., 2013) and isolated small molecules 
(Figure I-7A). Among them, #1 and #6 were potent inhibitors of the loading of 
oAβ1-42 onto FcγRIIb-ED in an in vitro binding assay (Figure I-7B) and 
efficiently competed with the in vitro binding of FITC-oAβ1-42 to FcγRIIb-ED 
(Figure I-7C). The neuronal uptake and neurotoxicity of oAβ1-42 were also 
curtailed by the treatment with #1 or #6 (Figure I-8). Moreover, memory deficits 
attributed to the intracerebroventricular injection of oAβ1-42, such as spatial 
memory (Figure I-9A) and recognition memory (Figure I-9B), were mitigated 
by the administration of #6. Together, these results illustrate that the binding of 
oAβ1-42 to FcγRIIb is required for Aβ internalization and neurotoxicity. 
 
Reduction of neuronal Aβ1-42 in 3x Tg-AD mice by Fcgr2b gene deletion  
It is known that 3x Tg-AD mouse model displays the early accumulation of 
intraneuronal Aβ with memory decline prior to extracellular amyloid deposition 
and neurofibrillary tangle formation (Oddo et al., 2003). To address the role of 
FcγRIIb in the accumulation of neuronal Aβ in these mice, I examined the 
presence of neuronal Aβ in the brains of 3x Tg-AD mice and 3x Tg-AD/Fcgr2b 
KO mice at 7 months of age in which 3x Tg-AD mice show impaired memory 
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function. Immunohistochemistry (IHC) using MOAB-2 antibody, which 
specifically recognizes Aβ but not APP (Youmans et al., 2012), revealed that 
Aβ signal was detected in the neurons of the hippocampal CA1 regions of 3x 
Tg-AD mice but not much in 3x Tg-AD/Fcgr2b KO mice (Figure I-10), 
indicating that the accumulation of neuronal Aβ in 3x Tg-AD mice requires 
FcγRIIb. 
I further analyzed alteration of the overall Aβ levels in the AD mouse model 
with ELISA. The level of TBS-extracted soluble Aβ1-42, but not Aβ1-40, was 
significantly lower in the hippocampus of 3x Tg-AD/Fcgr2b KO mice than 3x 
Tg-AD mice at 7 months of age (Figure I-11A). On the contrary, there was no 
difference in the levels of guanidine-extracted insoluble Aβ1-40 and Aβ1-42 
between 3x Tg-AD and 3x Tg-AD/Fcgr2b KO mice (Figure I-11B). 
Consequently, the prominent difference in the ratio of Aβ1-42 to Aβ1-40 between 
3x Tg-AD and 3x Tg-AD/Fcgr2b KO mice was observed in the soluble fraction 
(Figure I-11C). I confirmed no differences in the levels of full-length APP, APP 
C-terminal fragment α (APP-CTFα), APP C-terminal fragment β (APP-CTFβ), 
and APP intracellular domain (AICD) between 3x Tg-AD and 3x Tg-
AD/Fcgr2b KO mice (Figure I-12). These results indicate that FcγRIIb KO 
reduces soluble Aβ1-42 in the hippocampus of 3x Tg-AD mice without altering 




Alleviation of memory deficits in 3x Tg-AD mice by neuron-specific 
expression of Aβ uptake-defective Fcgr2b mutant 
Despite in vivo alteration in the intraneuronal Aβ by Fcgr2b deficiency, it was 
not certain yet whether Aβ uptake and memory deficits were dependent on the 
FcγRIIb in neurons. I thus generated transgenic mice expressing Fcgr2b-
deletion mutant (Fcgr2b-CytΔ Tg) only in forebrain neurons under the control 
of the calcium/calmodulin-dependent protein kinase II alpha subunit (CamKIIα) 
promoter (Tsai et al., 2010). The Fcgr2b-CytΔ mutant consists of the 
extracellular domain and transmembrane region but lacks the cytoplasmic 
region of FcγRIIb and is predicted to be defective in Aβ uptake and compete 
with the endogenous FcγRIIb for binding to Aβ. I confirmed that oAβ1-42-
induced neurotoxicity was reduced by the expression of Fcgr2b-CytΔ in HT22 
hippocampal cells (Figure I-13A). As expected, the expression of Fcgr2b-CytΔ 
in the Tg mice was restricted to the forebrain regions, including cortex and 
hippocampus (Figure I-13B).  
IHC assay showed that Aβ-specific MOAB-2 signal which was colocalized 
with synaptic protein synaptophysin and neuron-specific enolase (NSE) in the 
hippocampus and cortex of 3x Tg-AD mice, respectively, was weakened in 3x 
Tg-AD/Fcgr2b-CytΔ Tg mice (Figures I-14A and B). Reduction of neuronal Aβ 
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signal in 3x Tg-AD mice by Fcgr2b-CytΔ expression was more extensive in the 
hippocampus than in the cortex (Figures I-14C and D). Similarly, IHC using 
4G8 antibody also showed decreased intraneuronal Aβ in the hippocampus of 
3x Tg-AD mice by Fcgr2b-CytΔ expression (Figures I-15A and B). Moreover, 
the hippocampal synaptic dystrophy represented by synaptophysin was rescued 
in the same mice by Fcgr2b-CytΔ expression (Figure I-14E). As seen in Fcgr2b 
KO mice, the level of soluble Aβ1-42, but not soluble Aβ1-40 and insoluble Aβ1-
40 or Aβ1-42 (Figures I-16A and B), and the ratio of Aβ1-42 to Aβ1-40 in the soluble 
fraction (Figure I-16C) were significantly reduced in the hippocampus of 3x Tg-
AD mice by Fcgr2b-CytΔ expression. These changes were not elicited by the 
regulation of APP processing (Figure I-17). Thus, accumulation of soluble Aβ1-
42 in 3x Tg-AD mice was apparently suppressed by Fcgr2b-CytΔ expression. 
Since the intraneuronal and soluble oAβ1-42 have long been implicated in the 
memory deficits of AD (Billings et al., 2005; Shankar et al., 2008), I evaluated 
memory function in these mice. 3x Tg-AD/Fcgr2b-CytΔ Tg mice exhibited 
better spatial recognition function than 3x Tg-AD mice in Y-maze test (Figure 
I-18A). Deficit in recognition memory of 3x Tg-AD mice assessed by novel 
object recognition test was ameliorated by the neuronal expression of Fcgr2b-
CytΔ (Figure I-18B). In addition, defects in learning the connection between 
aversive foot shock and dark chamber in 3x Tg-AD mice were rescued by 
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Fcgr2b-CytΔ expression (Figure I-18C). Collectively, the neuronal function of 
FcγRIIb contributes to AD-like pathology, including learning and memory 
impairments, in 3x Tg-AD mice with the accumulation of neuronal Aβ1-42. 
 
Promotion of oAβ1-42 uptake via FcγRIIb2 variant is linked to neurotoxicity 
Interestingly, in the mouse brain I found an alternative splicing variant of 
FcγRIIb, FcγRIIb2 which has high activity in the receptor-mediated 
endocytosis, by sequencing cDNA generated from FcγRIIb transcript (Hunziker 
and Fumey, 1994). FcγRIIb2 mRNA was exclusively detected in the 
hippocampus and cortex, whereas FcγRIIb1 mRNA was found in the spleen and 
thymus (Figure I-19A). In particular, FcγRIIb2 mRNA was dramatically 
increased in the oAβ1-42-treated primary neurons (Figure I-19B). Examination 
of the FcγRIIb2 activity revealed that cellular uptake of oAβ1-42 was enhanced 
by the stable expression of FcγRIIb2 in SH-S Y5Y cells, while Aβ1-42 in the 
culture media was concomitantly reduced (Figure I-20). Notably, the ability of 
FcγRIIb2 to uptake oAβ1-42 was higher than FcγRIIb1 in HT22 and SH-SY5Y 
cells (Figure I-21). In accordance with the results observed in Fcgr2b KO 
neurons, internalization of oAβ1-42 over oAβ1-40 was selectively promoted by 
FcγRIIb2 expression in SH-SY5Y cells (Figure I-22). Thus, FcγRIIb2 functions 
to internalize oAβ1-42 into neurons efficiently. 
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To address how FcγRIIb2 internalizes oAβ1-42, I first focused on the di-
leucine motif, which is critical for the endocytosis of immune complex 
(Hunziker and Fumey, 1994), in the cytoplasmic domain of FcγRIIb2. I 
substituted the 274th and 275th leucine residues with alanine (L274A/L275A) 
and validated this mutant. Unlike FcγRIIb2 WT, oAβ1-42 uptake was not 
stimulated by FcγRIIb2 L274A/L275A expression (Figure I-21B). Since Fcgr2b 
KO neurons have been shown to be resistant to Aβ neurotoxicity (Kam et al., 
2013) and lack of intraneuronal Aβ (Figure I-3B), I performed an inverse 
analysis. While the overexpressed FcγRIIb2 WT and FcγRIIb2 L274A/L275A 
themselves did not affect cell viability, only FcγRIIb2 WT, but not FcγRIIb2 
L274A/L275A or FcγRIIb1, decreased cell viability in the presence of oAβ1-42 
(Figure I-23A). In addition, treatment with monodansylcadaverine, an inhibitor 
of clathrin-mediated endocytosis (Chen et al., 2009), suppressed oAβ1-42-
induced cell death and oAβ1-42 internalization in HT22 cells (Figure I-23B). 
Together, these results suggest that the di-leucine motif of FcγRIIb2 is essential 
for Aβ uptake and neurotoxicity.  
 
FcγRIIb2-mediated Aβ uptake is negatively regulated by TOM1 
I further characterized the FcγRIIb2-mediated Aβ uptake by isolating 
regulator(s) involved in this process. I established a cell-based assay for oAβ1-
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42 neurotoxicity and screened a cDNA expression library encoding endo-
lysosome-resident proteins. From the screening, Target of Myb 1 (TOM1) was 
the most potent in suppressing oAβ1-42-induced neurotoxicity in primary 
neurons and HT22 cells (Figure I-24). Ectopic expression of TOM1 also 
suppressed cell death triggered by ER stress which is downstream of FcγRIIb in 
oAβ1-42 neurotoxicity (Kam et al., 2013), but not by oxidative stress and TNF-
α/cycloheximide (Figure I-24C). Interestingly, oAβ1-42 uptake into SH-SY5Y 
cells and FcγRIIb2-mediated oAβ1-42 uptake were all inhibited by TOM1 
expression (Figure I-25A), whereas FcγRIIb2-mediated oAβ1-42 uptake was 
enhanced by TOM1 knockdown (Figure I-25B), indicating that TOM1 
negatively regulates cellular uptake and neurotoxicity of oAβ1-42.  
To address the function of TOM1 in regulating the FcγRIIb-mediated Aβ 
uptake, I analyzed the subcellular localization of FcγRIIb dependent on the 
expression of TOM1 and Aβ treatment. Since endocytosed FcγRIIb2 goes 
through the recycling pathway to the plasma membrane (Bergtold et al., 2005), 
I hypothesized that TOM1 may regulate FcγRIIb2 translocation along the 
endocytic pathway. In SH-SY5Y cells, FcγRIIb2 located in the recycling 
endosome with Rab11a was increased by TOM1 knockdown (Figure I-26A). I 
also found that FcγRIIb2 located in the plasma membrane was markedly 
increased in TOM1 knockdown SH-SY5Y cells, while FcγRIIb2 was 
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internalized into the post-plasma membrane fraction in response to Aβ (Figure 
I-26B). These results argue that the increment of FcγRIIb2 recycling to the 
plasma membrane leads to facilitation of oAβ1-42 uptake. 
I next assessed how TOM1 regulated Aβ uptake. Co-immunoprecipitation 
assay revealed that FcγRIIb2-FLAG bound to HA-TOM1 in the transfected cells 
and vice versa (Figure I-27). Besides, I found that endogenous FcγRIIb2 bound 
to TOM1 in HT22 cells and this interaction was weakened by oAβ1-42 treatment 
(Figure I-28A). To determine a pathophysiological relevance of this 
observation, I analyzed the FcγRIIb2-TOM1 interaction in AD brains. FcγRIIb2 
bound to TOM1 in the hippocampal lysates of non-AD controls and this 
interaction was significantly diminished in the AD brains (Figure I-28B). I also 
found that TOM1 level was reduced in the hippocampus of patients with AD 
compared with non-AD controls and was reduced by oAβ1-42 treatment in HT22 
cells (Figure I-29). To sum up, TOM1 binds to FcγRIIb2 and declined level of 
TOM1 might facilitate Aβ uptake during AD progression.  
 
Massive influx of Aβ into lysosome elicits Aβ overflow to other 
compartments for neurotoxicity 
To address how the internalized Aβ exhibits neurotoxicity, I assessed 
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degradation event of the internalized Aβ. As reported (Caglayan et al., 2014), 
the inhibition of lysosomal activity with bafilomycin A1 (Baf A1), a vacuolar-
type H+-ATPase inhibitor, resulted in the accumulation of FITC-oAβ1-42 in the 
DND-99-positive lysosomes of SH-SY5Y cells (Figure I-30A). As a 
comparable control, prevention of receptor-mediated endocytosis with MβCD 
showed accumulation of FITC-oAβ1-42 on the plasma membrane. Again, 
fractionation assay following brief exposure to oAβ1-42 revealed that the 
degradation of internalized Aβ was blocked by the treatment with Baf A1 or 3-
MA, an autophagy inhibitor, but not by MG132, a proteasome inhibitor (Figure 
I-30B). Hence, most of the internalized Aβ is degraded in the lysosome. 
Actually, a low dose of intraneuronal oAβ1-42 was rapidly degraded at an early 
time without affecting cell viability. In contrast, treatment of high and 
neurotoxic dose of oAβ1-42 resulted in a drastic accumulation of oAβ1-42 in the 
lysosome (Figure I-31A). Similar accumulation was also observed by the 
overexpressed FcγRIIb2 which caused massive internalization of oAβ1-42 
(Figure I-31B). Accordingly, lysosomal accumulation of oAβ1-42 was reduced 
by Fcgr2b KO in hippocampal neurons (Figure I-32). Collectively, excess 
uptake of Aβ exceeds the degrading capacity of lysosomes, causing degradation 
failure and accumulation in the lysosome. 
As reported (Friedrich et al., 2010; Kandimalla et al., 2009), I found 
17 
 
significant amounts of Aβ in the mitochondria and cytoplasm (Figure I-33A). 
Moreover, these subcellular localizations of Aβ were greatly reduced by Fcgr2b 
KO in primary neurons. Quantitative analysis using ELISA revealed that Aβ 
level in the cytoplasmic fraction was reduced by FcγRIIb deficiency, while it 
was 50% in the membrane-enriched fraction (Figure I-33B). Furthermore, the 
contribution of cytosolic Aβ to neurotoxicity was assessed by utilizing NIa, a 
cytoplasmic Aβ protease (Shin et al., 2014). Both neuronal death initiated by the 
treatment with oAβ1-42 and intraneuronal Aβ levels found in the cytoplasmic and 
mitochondrial fractions were simultaneously reduced by the expression of NIa, 
not by NIa D81A activity-dead mutant (Figure I-34). These results indicate that 
the cytoplasmic and mitochondrial Aβ originating from oAβ1-42 uptake via 
FcγRIIb2 contribute to neurotoxicity.  
 
FcγRIIb2 is essential for oAβ1-42 uptake and interneuronal propagation 
I further evaluated whether FcγRIIb2 played a role in the propagation of Aβ into 
adjacent neurons at the synapse. I established a fluidic isolation of donor and 
recipient neurons utilizing microfluidic chambers which are widely utilized in 
cell-to-cell transmission experiments of other aggregation-prone proteins, 
including α-synuclein (Freundt et al., 2012) (Figure I-35A). The internalized 
oAβ1-42 in hippocampal neurons in the donor chamber was transmitted to the 
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recipient neurons via synaptic connection (Figure I-35B). In contrast, this 
propagation was remarkably reduced when Fcgr2b KO neurons were loaded in 
the donor chamber (Figure I-35B and D). Moreover, oAβ1-42 transmission was 
severely affected by placing Fcgr2b KO neurons in the recipient chamber or 
both donor and recipient chambers (Figures I-35B and D). In addition, 
immunostaining analysis revealed that FITC-oAβ1-42 was co-localized with 
synaptophysin in WT neurons, but not in Fcgr2b KO neurons (Figure I-35C), 
confirming the propagation of FITC-Aβ1-42 between neurons. Therefore, oAβ1-
42 uptake through FcγRIIb2 in the presynaptic or postsynaptic neurons is critical 




Figure I-1. Neuronal uptake of Aβ1-42 oligomer determined by subcellular 
fractionation assay.  
(A) Establishment of an assay determining internalized Aβ level based on 
subcellular fractionation. SH-SY5Y cells were treated with 2.5 μM oAβ1-42 for 
1.5 h and then subjected to subcellular fractionation analysis. All fractions (Nu., 
nucleus; Cyto., cytoplasm; Mito., mitochondria; Memb., membrane) were 
confirmed by western blotting using CHDH (mitochondria), LC3 
(autophagosome), BiP (ER), Flotilin (lipid raft), and GM130 (Golgi apparatus) 
antibodies. (B) Preferential uptake of oAβ1-42 in primary neurons. Primary 
mouse hippocampal neurons and astrocytes were treated with vehicle (Veh.), 1 
μM mAβ1-42, or 1 μM oAβ1-42 for 12 h. The membrane-enriched fraction and 








Figure I-2. Preferential uptake of Aβ1-42 oligomers over Aβ1-42 monomer in 
primary neurons.  
(A) Representative confocal images of internalized mAβ1-42 and oAβ1-42 in 
primary neurons and astrocytes. Primary murine hippocampal neurons at 10 
DIV and astrocytes were incubated with 1.25 μM mAβ1-42 or oAβ1-42 for 18 h. 
Neurons and astrocytes were then analyzed by immunocytochemistry using 
MAP2b and GFAP antibodies, respectively. Scale bar, 50 μm. (B and C) 
Quantification of FITC-Aβ1-42 signal intensity in primary neurons (B) and 
astrocytes (C). At least 25 cells per each group were scored. **p < 0.01, ***p < 









Figure I-3. FcγRIIb plays a role in the neuronal uptake of Aβ1-42 oligomers. 
(A) Involvement of FcγRIIb in the neuronal uptake of Aβ1-42 oligomers. Cortical 
neurons and astrocytes were treated with 1 μM mAβ1-42 or oAβ1-42. Intracellular 
Aβ level in the membrane-enriched fraction was determined. (B and C) 
Intracellular accumulation of oAβ1-42 in WT MAP2B-positive neurons but not 
in Fcgr2b KO neurons. Primary neurons were incubated with 1.25 μM mAβ1-42 
or oAβ1-42 for 18 h. Scale bar, 50 μm (B). Comparison of intraneuronal FITC-
Aβ1-42 signals of WT and Fcgr2b KO neurons (n > 25 cells per each group) (C). 







Figure I-4. Validation of FcγRIIb-mediated uptake of Aβ1-42 oligomers in a 
time-course. 
Time-dependent internalization of oAβ1-42 by FcγRIIb. Aβ signals on the blots 
in (A) were quantified (B) (n = 3). *p < 0.05, **p < 0.01, ***p < 0.005. Bars 









Figure I-5. Accumulation of oligomeric Aβ1-42, not Aβ1-40, was blocked in 
Fcgr2b knockout neurons. 
(A) Preferential uptake of oAβ1-42 over oAβ1-40 by FcγRIIb. Cortical neurons 
were treated with 1 μM oAβ1-40 or oAβ1-42 for 1.5 h. (B and C) Internalization 
of cell-derived Aβ1-42 by FcγRIIb. Cortical neurons were incubated for 24 h with 
the conditioned media prepared from 7PA2 cells. Aβ1-40 (B) and Aβ1-42 (C) in 
lysates and conditioned media were measured by ELISA (n = 4). **p < 0.01. 









Figure I-6. FcγRIIb-Aβ1-42 oligomer interaction is critical for the neuronal 
uptake of Aβ1-42 oligomer. 
(A) Binding of oAβ1-42 to FcγRIIb is indispensable for its uptake. SH-SY5Y 
cells were incubated with 1 μM oAβ1-42 alone or together with 3 mg (1:1) or 9 
mg (1:3) purified FcγRIIb–ED protein for 1.5 h. (B) Requirement of FcγRIIb 
immunoglobulin (Ig) 2 domain in oAβ1-42 internalization. SH-SY5Y cells were 
transfected with pEGFP-N1 (Mock), pFcγRIIb2-GFP, pFcγRIIb2 Ig1 deletion 
mutant-GFP (ΔIg1), or pFcγRIIb2 Ig2 deletion mutant-GFP (ΔIg2) for 24 h and 
then treated with 1 μM oAβ1-42 for 1.5 h. The membrane-enriched fractions were 








Figure I-7. Isolation of small molecules blocking interaction between 
FcγRIIb and Aβ1-42 by virtual screening. 
(A) Structural formula of #1 and #6, putative blockers of FcγRIIb2-Aβ1-42 
interaction. (B) Inhibition of FcγRIIb-ED-Aβ interaction by small molecules #1 
and #6. Purified FcγRIIb-ED protein (15 μg/ml) was incubated with Aβ in the 
absence or presence of 100 nM small molecules and the reaction was subjected 
to pull-down assay. (C) Inhibition of FITC-oAβ1-42-FcγRIIb-ED interaction by 
small molecules #1 and #6. Culture plate coated with 15 μg/ml FcγRIIb-ED 
protein was first incubated with FcγRIIb-ED, FcγRIIb antibody, or 100 nM 
small molecule (#1, #6, and #5) and then with 5 μM FITC-oAβ1-42 (n = 6). After 
washing with PBS, the fluorescence of FITC remaining on the plate was 









Figure I-8. Aβ internalization and neurotoxicity are suppressed by putative 
FcγRIIb2-Aβ1-42 interaction blocker. 
(A) Inhibition of Aβ internalization by small molecules #1 and #6. Primary 
neurons were pre-treated with small molecules #1, #4 or #6 for 1.5 h, and then 
incubated with 1 μM oAβ1-42 for 1.5 h. Intraneuronal Aβ in the membrane-
enriched fraction (Fraction) and residual Aβ in the conditioned media (Media) 
were determined by western blotting. (B) Inhibition of Aβ neurotoxicity by 
small molecules #1 and #6. HT22 cells were pre-treated with the indicated 
concentrations of small molecules for 1.5 h, and then incubated with 5 μM oAβ1-









Figure I-9. Amelioration of cognitive impairment in Aβ-injected mice by 
small molecule #6. 
Five week-old WT mice were i.c.v. injected with vehicle (Veh.) or 2 μg oAβ1-42 
in the presence of 0.615 μg small molecule #6 and analyzed by Y maze (A) and 
novel object recognition (B) tests (n = 6 per each group).  









Figure I-10. Reduction of intraneuronal Aβ1-42 in 3x Tg-AD mice by Fcgr2b 
gene deletion.  
Intraneuronal Aβ in the CA1 of the hippocampus of 7 month-old 3x Tg-AD and 
3x Tg-AD/Fcgr2b KO mice were detected using MOAB-2 antibody with 200x 
(A) and 400x (B) and quantified (C) (n = 6). Scale bar, 50 μm (A) and 20 μm 









Figure I-11. Soluble Aβ1-42 in the hippocampus of 3x Tg-AD mice is reduced 
by genetic deletion of Fcgr2b.  
Reduction of soluble Aβ1-42, not insoluble Aβ1-42, by Fcgr2b KO in 3x Tg-AD. 
The hippocampal extracts of 7 month-old 3x Tg-AD and 3x Tg-AD/Fcgr2b KO 
mice were prepared in TBS (A) or 5 M guanidine hydrochloride (GDN) (B), 
and the concentrations of Aβ1-40 and Aβ1-42 were then measured (n = 4). Aβ1-









Figure I-12. No differences in APP processing between 3x Tg-AD and 3x 
Tg-AD/Fcgr2b KO mice.  
Levels of APP, APP-CTFα (CTFα), APP-CTFβ (CTFβ) and AICD in the 
hippocampus of both 3x Tg-AD and 3x Tg-AD/Fcgr2b KO mice at the age of 









Figure I-13. Generation of forebrain neuron-specific Fcgr2b-CytΔ Tg mice.  
(A) Inhibition of oAβ1-42-elicited cell death by the expression of Fcgr2b-CytΔ. 
HT22 cells were transfected with pEGFP-N1 (GFP) or pFcγRIIb-CytΔ-GFP 
(Fcgr2b-CytΔ) for 12 h and then treated with 5 μM oAβ1-42 (n = 3). (B) 
Forebrain neuron-specific expression of Fcgr2b-CytΔ transgene by CamKIIα 
promoter. Cortex, hippocampus, and cerebellum of WT and Fcgr2b-CytΔ Tg 
mice at the age of 3 months were analyzed by western blotting. *p < 0.05. Bars 









Figure I-14. Neuronal expression of Fcgr2b-CytΔ in 3x Tg-AD mice 
decreases MOAB-2-positive intraneuronal accumulation of Aβ1-42. 
Intraneuronal Aβ in the CA1 of the hippocampus (A) and cortex (B) of 8 month-
old 3x Tg-AD and 3x Tg-AD/Fcgr2b-CytΔ Tg mice were detected using 
MOAB-2 (Representative confocal images, 200x, Scale bar, 50 μm). 
Reactivities of the MOAB-2 in the hippocampal CA1 (C) and cortex (D) and of 
the synaptophysin in the hippocampal CA1 (E) were quantified. **p < 0.01, 








Figure I-15. Neuronal expression of Fcgr2b-CytΔ in 3x Tg-AD mice 
decreases 4G8-positive intraneuronal accumulation of Aβ1-42. 
Immunofluorescent detection of intraneuronal Aβ in the CA1 region of the 
hippocampus of 8 month-old 3x Tg-AD and 3x Tg-AD/Fcgr2b-CytΔ Tg mice 








Figure I-16. Soluble Aβ1-42 in the hippocampus of 3x Tg-AD mice is reduced 
by neuronal expression of Fcgr2b-CytΔ. 
The concentrations of Aβ1-40 and Aβ1-42 in the hippocampal extracts prepared in 
TBS (A) and 5 M guanidine hydrochloride (GDN) (B) from 3x Tg-AD and 3x 
Tg-AD/Fcgr2b-CytΔ mice at 8 months of age (n = 4) were measured. Aβ1-
42/Aβ1-40 ratios in (A) and (B) were calculated (C). *p < 0.05. Bars represent 









Figure I-17. No differences in APP processing between 3x Tg-AD and 3x 
Tg-AD/Fcgr2b-CytΔ mice. 
Levels of APP, APP-CTFα (CTFα), APP-CTFβ (CTFβ), and AICD in the 
hippocampus of both 3x Tg-AD and 3x Tg-AD/Fcgr2b-CytΔ mice at the age of 








Figure I-18. Alleviation of memory deficits in 3x Tg-AD mice by neuron-
specific expression of Aβ uptake-defective Fcgr2b mutant. 
Alleviation of cognitive impairment in 3x Tg-AD mice by neuronal expression 
of Fcgr2b-CytΔ. The Y-maze (A), novel object recognition (B), and passive 
avoidance (C) tests were performed in 7 month-old mice (n = 9-11 male mice 









Figure I-19. Enriched transcription of FcγRIIb variant 2 in neurons. 
(A) Expression pattern of FcγRIIb2 in the brain tissues. Total RNAs isolated 
from the hippocampus (Hippo.), cortex, spleen, and thymus of WT and Fcgr2b 
KO mice were analyzed by RT-PCR. (B) Neuronal expression of the FcγRIIb2 
variant revealed by RT-PCR. Cortical neurons were treated with 1 μM mAβ1-42 








Figure I-20. Increased internalization of oAβ1-42 by FcγRIIb2 stable 
expression. 
The amounts of Aβ in the membrane-enriched fraction (Fraction) and 
conditioned media (Media) were examined (A) and the signals on the blots were 
quantified (n = 3) (B, C). *p < 0.05, **p < 0.0. Bars represent mean ± SD. N.S, 









Figure I-21. Enhanced internalization of oAβ1-42 by the expression of 
FcγRIIb2 is dependent on its di-leucine motif. 
(A) FcγRIIb2-mediated cellular uptake of oAβ1-42. HT22 and SH-SY5Y cells 
were transfected with pEGFP-N1, pFcγRIIb1-EGFP or pFcγRIIb2-EGFP for 36 
h, and treated with 1 μM oAβ1-42 for 1.5 h. The Aβ levels in the membrane-
enriched fraction (Fraction) and conditioned media (Media) were determined by 
western blotting. (B) FcγRIIb2 di-leucine residues critical in Aβ uptake. SH-
SY5Y cells were transfected with the indicated constructs for 24 h and then 








Figure I-22. Internalization of oAβ1-42, not oAβ1-40, is promoted by 
FcγRIIb2. 
Distinct uptake of oAβ1-42 and oAβ1-40 via FcγRIIb2. SH-SY5Y cells were 
transfected with pEGFP-N1 or pFcγRIIb2 for 36 h, and treated with 1 μM oAβ1-








Figure I-23. Di-leucine motif of FcγRIIb2 required for Aβ uptake is critical 
for neurotoxicity. 
(A) Enhanced Aβ internalization by FcγRIIb2 induces neuronal death. Cortical 
neurons were transfected with the constructs for 24 h and incubated with vehicle 
(Veh.), 1 μM mAβ1-42, or 1 μM oAβ1-42 for 36 h (n = 3). (B) Suppression of 
oAβ1-42–induced neurotoxicity by the inhibition of clathrin-mediated 
endocytosis. SH-SY5Y cells were preincubated with 100 μM 
monodansylcadaverine (MDC) for 1 h and then treated with 1 μM oAβ1-42 for 
36 h (left panel) or 12 h (right panel). Cell death rates (left panel, n = 4; p < 
0.001 by ANOVA) and the Aβ levels in the membrane-enriched fraction 
(Fraction) and conditioned media (Media) were determined. *p < 0.05, **p < 









Figure I-24. Isolation of TOM1 as a genetic reliever of Aβ neurotoxicity by 
functional screening. 
(A) Dot plot describing cell-based functional screening to isolate the modulators 
of oAβ1-42–induced neurotoxicity in HT22 cells. (B) Inhibition of Aβ1-42 
oligomer-induced neuronal death by TOM1. The pEGFP-C1 (Mock) or pEGFP-
TOM1-transfected hippocampal neurons were incubated with 5 μM oAβ1-42 for 
36 h (n = 3). (C) Inhibition of oAβ1-42- and ER stress-induced neuronal death by 
TOM1. HT22 cells were transfected with pEGFP-C1 (Mock) or pEGFP-TOM1 
for 16 h and treated with 5 μM oAβ1-42 for 36 h (left panel) or thapsigargin (Tg) 
for 12 h, 300 μM H2O2 for 18 h or both 30 ng/ml TNF-α and 10 μg/ml 
cycloheximide (CHX) for 18 h (right panel) (n = 3). *p < 0.05, ***p < 0.005. 






















Figure I-25. FcγRIIb2-mediated Aβ uptake is negatively regulated by 
TOM1.  
(A) Inhibition of FcγRIIb2-mediated Aβ uptake by TOM1. SH-SY5Y cells were 
transfected with indicated plasmids and treated with 1 μM Aβ1-42 for 1.5 h. (B) 
Enhancement of FcγRIIb2-mediated Aβ uptake by TOM1 knockdown. SH-
SY5Y stable cells expressing pSUPER-neo (Mock) or pTOM1 shRNA 
(shTOM1) were transfected with pFcγRIIb2-GFP for 48 h and treated with 








Figure I-26. FcγRIIb2 recycling to plasma membrane is attenuated by 
TOM1.  
(A) Membrane-retargeting of endocytosed FcγRIIb2 via recycling endosome is 
enhanced by TOM1 knockdown. pFcγRIIb2-RFP and pRab11a-GFP transfected 
SH-SY5Y/Mock and SH-SY5Y/shTOM1 were incubated with 1 μM oAβ1-42 for 
6 h. Scale bar, 20 μm. (B) Localization of FcγRIIb2 to the plasma membrane is 
elevated by TOM1 knockdown. SH-SY5Y/Mock and SH-SY5Y/shTOM1 cells 
were treated with PBS or 1 μM oAβ1-42 for 12 h. Lysates were subjected to 









Figure I-27. Interaction between overexpressed FcγRIIb2 and TOM1.  
HEK293T cells were transfected with pFcγRIIb2-FLAG and pHA-TOM1 for 
24 h and subjected to immunoprecipitation (IP) assay using FLAG (C) or HA 























Figure I-28. Endogenous interaction between FcγRIIb2 and TOM1 is 
decreased in neurons by Aβ1-42 oligomer and in AD brain.  
(A) Blockade of the FcγRIIb-TOM1 interaction by oAβ1-42. Whole cell lysates 
(WCL) of HT22 cells were immunoprecipitated (IP) using IgG or FcγRIIb 
antibody. (B) Decreased interaction between FcγRIIb2 and TOM1 in the 
hippocampus of AD patients. Hippocampal lysates were subjected to 
immunoprecipitation (left panel). Level of TOM1-interacting FcγRIIb on the 










Figure I-29. Protein level of TOM1 is decreased by Aβ1-42 oligomer and in 
AD brain.  
(A) Decrease of TOM1 expression by oAβ1-42. SH-SY5Y cells were treated with 
1 μM oAβ1-42 for 24 h (n = 3). (B) Decreased expression of TOM1 in the 
hippocampus of AD patients. Hippocampal homogenates were analyzed by 
western blotting (left panel) and quantified (right panel; n = 9 for Non-AD 
controls and n = 15 for AD patients). *p < 0.05, ***p < 0.005. Bars represent 


















Figure I-30. Internalized Aβ1-42 is degraded in the lysosome.  
(A) Inhibition of lysosome leads to accumulation of Aβ1-42 in the lysosome. SH-
SY5Y cells were incubated with 250 nM FITC-oAβ1-42 and vehicle (Veh.), 0.5 
mM methyl-β-cyclodextrin (MβCD), or 10 nM Baf.A1 for 2 h and then treated 
with 50 nM Lysotracker Red (DND-99) for 1 h. Arrow indicates stacked Aβ in 
activity prevents degradation of the internalized Aβ. SH-SY5Y cells were 
treated with 1 μM oAβ1-42 for 12 h and further incubated with Aβ1-42-free 
medium and vehicle (Veh.), 10 nM Baf. A1, 2.5 μM MG132, or 5 mM 3-MA 







Figure I-31. Promoted internalization of oAβ1-42 by FcγRIIb2 is linked to 
its cellular accumulation. 
(A) Accumulation pattern of high or low-dose of oAβ1-42. SH-SY5Y cells were 
treated with 1 or 5 μM oAβ1-42 for 12 h, and then incubated with Aβ1-42-free 
medium for the indicated times in the presence of vehicle (Veh.) or 10 nM 
bafilomycin A1 (Baf. A1). The Aβ levels in the membrane-enriched fraction 
(Fraction) and conditioned media (Media) were determined. (B) Increase of 
internalized Aβ in FcγRIIb2-expressing neuronal cells. SH-SY5Y/Mock and 
SH-SY5Y/FcγRIIb2 cells were treated with 1 μM oAβ1-42 for 12 h and incubated 



















Figure I-32. Excessive uptake of Aβ mediated by FcγRIIb2 causes 
degradation failure and accumulation in the lysosome. 
(A) Accelerated degradation of internalized Aβ in Fcgr2b KO neurons. Cortical 
neurons were treated with 1 μM mAβ1-42 or oAβ1-42 for 12 h and incubated with 
Aβ1-42-free media. (B) Internalized Aβ1-42 accumulates in the lysosome through 
FcγRIIb. Hippocampal neurons were incubated with 1.25 μM mAβ1-42 or oAβ1-








Figure I-33. Reduction of Aβ in other cellular compartments by FcγRIIb 
deficiency. 
Cortical neurons were treated with 1 μM mAβ1-42 or oAβ1-42 for 18 h. The Aβ in 
the membrane-enriched (Memb.), mitochondrial (Mito.), and cytoplasmic 
(Cyto.) fractions were determined by western blotting (A) and ELISA (n = 3; p 









Figure I-34. Rescue of neuronal death by the degradation of cytoplasmic 
and mitochondrial Aβ.  
pcDNA3-HA (Mock), pNIa-HA (NIa), or pNIa D81A-HA (D81A) transfected 
cortical neurons were incubated with 1 μM oAβ1-42 for 12 h (left panel) or 36 h 
(right panel). The Aβ level in each fraction was measured as in (E) (left panel). 
Calcein-AM-positive viable cells were counted (right panel; n = 3; p < 0.01 by 








Figure I-35. FcγRIIb2 is critical for neuron-to-neuron spreading of oAβ1-42. 
(A) Schematic picture of a microfluidic chamber. (B and C) Deterred spreading 
of Aβ in neurons by FcγRIIb deficiency. FITC-oAβ1-42 signals in microfluidic 
chambers were detected with 50x (B) and 200x (C). Scale bars in (B) and (C) 
represent 200 μm and 5 μm, respectively. (D) Comparison of fluorescent 
intensities in the chambers plated with WT-to-WT and WT-to-Fcgr2b KO 











Increasing evidence showed that Aβ is internalized into various types of 
cells in the brain, including neurons, astrocytes, microglia, brain microvascular 
endothelia, and cerebrovascular smooth muscle cells (Kandimalla et al., 2009; 
LaFerla et al., 2007; Urmoneit et al., 1997). Nonetheless, the selectivity of Aβ 
species for cellular uptake into different cell types, the fate of internalized Aβ, 
and the pathophysiologic relevance of this process were not evaluated. The 
characteristics of Aβ species or strains differ from each other according to 
peptide length (Aβ1-40 or Aβ1-42), oligomeric states (monomer, low-n oligomer, 
high-n oligomer, or fibril), and source (synthetic Aβ, naturally secreted Aβ, or 
purified Aβ from pathogenic samples) (Benilova and De Strooper, 2013; Haass 
and Selkoe, 2007). Whether internalized Aβ is subjected to either degradation 
or exhibits neurotoxicity is also determined by its characteristics of above and 
cellular capacity to defense against it. Our findings that neuron has both high 
capacity to internalize oAβ1-42 and more propensity to internalize neurotoxic 
oAβ1-42 than nontoxic mAβ1-42 or oAβ1-40 provide an intriguing model that 
neuron itself could be a determinant for Aβ neurotoxicity. Regarding that 
astrocyte prefers mAβ1-42 to oAβ1-42, non-neuronal cells might degrade mAβ for 
the clearance.  
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The detrimental role of intraneuronal Aβ in AD progression was previously 
shown in 3x Tg-AD mice in which the accumulation of intraneuronal Aβ is 
temporally correlated with synaptic dysfunction and memory loss (Billings et 
al., 2005). In the same mice, I found that intraneuronal Aβ was remarkably 
decreased by Fcgr2b KO or neuron-specific expression of Fcgr2b-CytΔ at 7-8 
months of age. Parallel to the reduction in intraneuronal Aβ, synaptic density 
and memory decline were restored by Fcgr2b-CytΔ expression. Because 
amyloid plaques and tangles are not developed but both synaptic transmission 
and plasticity are impaired in 3x Tg-AD mice at 7 months of age (Oddo et al., 
2003), I propose that the reduction in intraneuronal Aβ in 3x Tg-AD/Fcgr2b KO 
mice and 3x Tg-AD/Fcgr2b-CytΔ Tg mice is mainly responsible for these 
improvements. Additionally, I also found that expression of Iba1, a microglia 
marker, and mRNA transcripts of pro-inflammatory genes, such as interleukin-
1 β (IL1β), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α 
(TNFα), were more or less reduced by Fcgr2b KO in the cortex and 
hippocampus of 3x Tg-AD mice (data not shown). At this moment, I do not have 
an evidence showing that the non-neuronal activity of FcγRIIb is not solely 
responsible for the memory impairment. But I believe that the 
neuroinflammation via microglial FcγRIIb might also contribute to the 
aggravation of memory impairment in AD mice. Further, the notion that soluble 
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Aβ1-42, but not insoluble Aβ1-42, was reduced in 3x Tg-AD mice by Fcgr2b KO 
or Fcgr2b-CytΔ expression suggests that intraneuronal Aβ exists as the 
oligomeric state or is involved in the Aβ oligomerization, consistent with the 
previous reports (Oddo et al., 2006; Takahashi et al., 2013). It will be interesting 
to evaluate the role of FcγRIIb2 in other AD mouse models, such as APP E693Δ 
mice that show extensive intraneuronal Aβ phenotype and AD-like memory 
defect without extracellular Aβ load (Tomiyama et al., 2010).  
The important question is how the internalized oAβ1-42 by FcγRIIb2 exhibits 
neurotoxicity. The process of FcγRIIb2-mediated oAβ1-42 uptake overlaps with 
or utilizes the di-leucine-dependent receptor-mediated endocytosis, leading to 
the accumulation of excess oAβ1-42 mainly in the lysosome and in the other 
cellular compartments as well. Although lysosome is an organelle for Aβ 
catabolism, massive influx of Aβ exceeding its capacity to degrade Aβ exhibited 
neurotoxicity, as shown in our assays, and caused the deregulation of lysosomal 
activity, as reported previously (Ling et al., 2009; Song et al., 2011). 
Furthermore, impairment of lysosomal activity by other factors, such as 
presenilin mutations (Lee et al., 2010), may further lower the catabolic activity 
against Aβ and thus increase the lysosome-associated neurotoxicity. Although I 
do not know the mechanism by which the internalized Aβ deregulates lysosome 
activity, I believe that the Aβ-induced lysosomal rupture leads to the leakage of 
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its contents and Aβ into multivesicular body and cytoplasm (Friedrich et al., 
2010; Umeda et al., 2011). Thus, cytoplasmic Aβ found in the neurons of AD 
patients and model mice might reflect this distribution of Aβ. 
Furthermore, our assays using microfluidic devices show that the neuronal 
uptake of oAβ1-42 also occurs at the synapse through FcγRIIb2 for its 
propagation. In this case, the internalized Aβ1-42 in the donor neurons bypasses 
lysosomal degradation, as previously evidenced by the report showing that 
failure in the removal of intraneuronal Aβ in the lysosome is related to the 
propagation of Aβ to connected neurons (Domert et al., 2014). Similarly, 
propagation of α-synuclein is promoted by insufficient clearance by autophagic 
inhibition, suggesting that the stereotypical spreading of aggregation-prone 
proteins is caused by common failures in the cellular degradative system (Lee 
et al., 2013). While endocytosis and synaptic activity were reported to be 
required for presynaptic release of Aβ in donor neurons (Cirrito et al., 2008; 
Tampellini et al., 2009), I propose that post-synaptic FcγRIIb2 is crucial for 
neuronal uptake of Aβ for synaptic transmission. Moreover, our previous 
observation that FcγRIIb2 is crucial for synaptic function, such as LTP, might 
associate with the proposed role of FcγRIIb2 in neuronal transmission of 
pathogenic Aβ. Whether FcγRIIb2 also plays a role in the propagation of other 
pathogenic proteins like α-synuclein (Choi et al., 2015) needs to be validated. 
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In conclusion, I found that the FcγRIIb2 variant is indispensable for Aβ 
neurotoxicity by mediating the neuronal uptake and intraneuronal accumulation 
of oAβ1-42, which affects AD neuropathology through its neuron-to-neuron 




Materials and methods 
Mice 
CaMKIIα-driven transgene of Fcgr2b-CytΔ was produced as previously 
described (Kasahara et al., 2006). Fcgr2b-CytΔ that lacks cytoplasmic region 
of intact Fcgr2b was amplified by PCR and ligated into EcoRV site of pNN265. 
The NotI cleavage product (2.2 kb) of the resulting construct contains Fcgr2b-
CytΔ flanked by 5′-UTR with SV40 small-T antigen intron and 3′-UTR with 
early polyadenylation sequence was ligated into pMM403 with CaMKIIα 
promoter. Injection of SfiI-linearized construct into fertilized eggs of C57BL/6J 
was performed by Macrogen (Korea). Fcgr2b KO and 3x Tg-AD mice were 
previously described (Oddo et al., 2003; Takai et al., 1996). Suitable numbers 
of samples were adapted from the previous reports using 3x Tg-AD mice 
(Castello et al., 2012; Sykora et al., 2015). Since female mice were responsive 
to behaviors dealing with novelty and anxiety due to higher corticosterone levels 
(Aoki et al., 2010), only male mice were utilized in memory tests. Data were 
collected and quantified by investigators with blindness. All animal experiments 
were performed under the guidelines of Seoul National University Institutional 




Human brain samples and ethical statement 
Hippocampal tissues from non-AD and AD (BraakV-VI) patients were obtained 
from the Harvard Brain Tissue Resource Center of McLean Hospital (Belmont, 
MA, USA). This study was approved by the Institutional Review Board of Seoul 
National University (SNUIRB No. E1212/001-006). 
 
Cell culture and DNA transfection 
Primary cortical and hippocampal neurons were prepared from embryonic day 
16 (E16) of mouse as described (Kam et al., 2013). Primary astrocytes were 
prepared form postnatal day 1 of mouse as described (Kim et al., 2013). Primary 
neurons were transfected using Lipofectamine 2000 reagent (Invitrogen), and 
SH-SY5Y, HT22 and HEK293T cells were transfected using Polyfect reagent 
(Qiagen) according to the manufacturer’s instructions. 
 
ELISA 
Mouse hippocampus was homogenized in TBS buffer (50 mM Tris pH 7.5, 150 
mM NaCl). The insoluble pellet was reconstituted in GDN buffer (50 mM Tris 
pH 8.0, 5 M guanidine hydrochloride). Hippocampal levels of Aβ1-40 and Aβ1-42 
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were measured by ELISA kit (IBL) according to the manufacturer’s instructions.  
 
Behavior tests 
Y maze - Y maze contains 3 equal arms (32.5 cm long x 15 cm high) made of 
black plastic with 120° interval. Mice were laid to the end of one arm and 
subjected to roam freely in the apparatus for 7 min. Arm entry was regarded as 
valid when whole body including tail is completely entered into each arm. 
Effective alteration was counted when mouse entered three different arms 
consecutively. Spontaneous alteration was assessed as the ratio of the number 
of effective alteration to the number of total arm entry. 
Novel object recognition - Novel object recognition was composed of 2 day 
habituation, 1 day training and 2 day test session. All sessions were performed 
at identical time in each days. In order to become familiar with the chamber (22 
cm wide x 27 cm long x 30 cm high), mice was allowed to freely roam in there 
for 10 min. At training phase, two objects were placed to upper right and lower 
left sides of the chamber and mice were subjected to recognize them for 7 min. 
During test phases, object located in the upper right side was replaced with the 
novel object once a day. During training and test phase, time spent with each 
object was measured. Discrimination ratio was calculated by dividing TUR by 
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sum of TUR and TLL, where TUR and TLL indicate the time spent with the object 
located in the upper right and lower left side of chamber, respectively.  
Passive avoidance - Passive avoidance was composed of 1 day habituation, 1 
day training and 1 day test session. All sessions were performed at identical time 
in each days. The apparatus (40 cm wide x 20 cm long x 20 cm high) consists 
of bright compartment which is lightened by overhead 8 W lamp and dark 
compartment whose floor is made of electrical grids. Two compartments are 
divided by a sliding door. At habitation session, mice were subjected to freely 
explore both compartment for 5 min. At training session, mice initially placed 
into the bright compartment was shocked by foot grid (0.25 mA, 1 s) shortly 
after entering into the dark compartment. At test session, the latency to enter the 
dark compartment was recorded. 
 
DNA construction  
Mouse Fcgr2b1 and Fcgr2b2 cDNA were amplified by PCR and ligated into 
pEGFP-N1 and pDsRed-N1. Human FCGR2B2 cDNA was amplified by PCR 
and ligated into pCMV5c-FLAG. The following nucleotide sequences were 
used as the primers: Fcgr2b-NheI-Sense (5′-CTA GCT AGC CAT GGA GAG 
CAA CTG GAC TGT-3′), Fcgr2b-KpnI-Antisense (5′-GGG GTA CCC CAA 
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TGT GGT TCT GGT AAT C-3′), FCGR2B2-BglII-Sense (5′-GGA AGA TCT 
TCC ATG GGA ATC CTG TCA TTC TT-3′), and FCGR2B2-KpnI-Antisense 
(5′-GGG GTA CCC AAT ACG GTT CTG GTC ATC A-3′). Mouse Fcgr2b2 
L274A/L275A mutant was generated by site-directed mutagenesis using 
following primers: Fcgr2b2 L274A/L275A-Sense (5′-CAC CTA CTC AGC 
TGC CAA GCA TCC CG-3′) and Fcgr2b2 L274A/L275A-Antisense (5′-CGG 
GAT GCT TGG CAG CTG AGT AGG TG-3′). Expression vectors of NIa WT 




Total RNA was extracted from primary neurons or mouse tissues using TRI 
reagent (MRC) and cDNA was generated using M-MLV reverse transcriptase 
(Enzynomics, Korea). To discriminate Fcgr2b1 and Fcgr2b2, a pair of primers 
for Fcgr2b were designed to encompass the sixth exons. The following 
nucleotide sequences were used as the primers for RT-PCR: Fcgr2b-RT-Sense 
(5′-CAG CGA CCT GTA GAT CTG GGA G-3′), Fcgr2b-RT-Antisense (5′-
CTT CAT CCA GGG CTT CGG GAT GC-3′), Actb-RT-Sense (5′-GAG CTG 






Prior to subcellular fractionation, cells were briefly treated with trypsin-EDTA 
for 5 min to remove non-specific Aβ from the plasma membrane. Cell lysates 
were homogenized in hypotonic buffer (250 mM Sucrose, 20 mM HEPES pH 
7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA) by passing through 25 gauge 
needle. Nuclei and cell debris were excluded as pellets by centrifugation at 
1,000xg for 10 min at 4ºC. Mitochondria fraction was isolated as a pellet by 
centrifugation of post-nucleus supernatants at 10,000 g for 10 min at 4ºC. The 
resulting supernatants were divided into the membrane-enriched fraction (pellet) 
and the cytoplasmic fraction (supernatant) by centrifugation at 100,000 g for 2 
h at 4ºC. Segregation of plasma membrane fraction was performed as described 
(Oh et al., 2012). CD49b serves as a plasma membrane marker in western 
blotting.  
 
In vitro pulldown assay 
In vitro interaction between oAβ1-42 and FcγRIIb-ED and its inhibition by small 
molecules were analyzed as described (Kam et al., 2013). Briefly, FcγRIIb-ED 
protein (15 μg/ml) was preloaded with 100 nM small molecules for 1 h in 
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binding buffer (50 mM Tris pH 7.4, 1 mM DTT, 0.5 mM EDTA, 0.01% Triton 
X-100, 10% glycerol). Then, oAβ1-42 (5 μg) was added to these mixtures for 2 h 
and subjected to the precipitation assay with FcγRIIb antibody preconjugated 
with protein G sepharoseTM (GE Healthcare). The precipitates were analyzed by 
western blotting. 
 
Western blotting and immunoprecipitation 
The following antibodies were used for western blotting and 
immunoprecipitation: Aβ (4G8 and 6E10, both Covance); BiP, Calnexin, CHDH, 
GFP, mouse FcγRIIb, TOM1, Ubiquitin, (Santa Cruz); Flotilin, GM130, TIM23, 
CD49b (BD biosciences); human FcγRIIb, LC3 (Novus); α-tubulin, β-actin, 
APP, FLAG (Sigma Aldrich); PHF1 (Courtesy of Dr. Peter Davies, Albert 
Einstein College of Medicine). Human hippocampal tissues for 
immunoprecipitation were solubilized in CHAPS lysis buffer (150 mM NaCl, 
1 % CHAPS, 2 mM EDTA, 25 mM HEPES pH 7.4). HT22 and HEK293T cell 
extracts for immunoprecipitation were solubilized in RIPA lysis buffer (150 mM 





Primary neurons and astrocytes were treated with 1.25 μM mAβ1-42 (1 μM non-
labeled mAβ1-42 mixed with 0.25 μM FITC-mAβ1-42) or oAβ1-42 (1 μM non-
labeled oAβ1-42 mixed with 0.25 μM FITC-oAβ1-42) for 18 h. Cells were treated 
with 500 μg/ml Trypan blue in PBS before paraformaldehyde fixation to prevent 
background fluorescence outside the cells (Dementhon et al., 2012). Antibodies 
for MAP2b (BD Biosciences) and GFAP (Millipore) were used to stain primary 
neurons and astrocytes, respectively. 
 
Assessment of cell viability and cell death 
Viable cells were stained with 0.5 μM Calcein-AM (Molecular Probes) which 
is originally non-fluorescent but converted to fluorescent form under hydrolysis 
by intracellular esterases in live cells. Otherwise, cell viability was assessed 
using EZ-CyTox cell viability kit (Daeil Lab Service, South Korea). Cell death 
in HT22 cells were assessed by counting GFP-positive cells showing apoptotic 
fractured nuclei characterized by ethidium homodimer-1 (Molecular Probe). 
 
Cell-based functional screening 
HT22 cells were transfected with each of 120 cDNAs encoding endo-lysosomal 
proteins for 24 h and further treated with 5 μM oAβ1-42 for 36 h. Alteration in 
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cell death according to each cDNA clones were determined to isolate the 
putative positive clones.  
 
Preparation of synthetic and cell-derived oAβ 
Synthetic oAβ were generated as described (Kam et al., 2013). Briefly, Aβ1-40, 
Aβ1-42, and FITC-Aβ1-42 peptides lyophilized from 1,1,1,3,3,3,-
hexafluoroisopropanol (rPeptide) were solubilized in DMSO at 2 mM and then 
diluted in PBS to final 125 μM. The Aβ freshly diluted was used as Aβ monomer. 
Aβ incubated at 4ºC for 24 h was centrifuged at 12,000 g for 10 min and the 
resulting supernatant was used as Aβ oligomers. Prepared synthetic oAβ was 
composed of low-n (1-4) Aβ oligomer with globular shape characterized by 
SDS-PAGE and atomic force microscope (Kam et al., 2013). Cell-derived Aβ 
was prepared from the conditioned media of CHO cells stably expressing V717F 
mutant APP (7PA2 cells) (Courtesy of Dr. D.J. Selkoe, Harvard Medical School, 
MA) as described (Walsh et al., 2002). Cell debris were removed by the 
centrifugation at 230 g for 10 min and proteins in subsequent supernatants were 





IHC analysis of mouse brains were accomplished as described (Youmans et al., 
2012). Brains were fixed with 4 % paraformaldehyde for 48 h and dehydrated 
with 30 % sucrose in PBS for 48 h. The 40-μm-thick floating sections were 
sliced on a CM1950 cryostat (Leica) and each section was allowed for antigen 
retrieval by incubating in 88 % formic acid for 8 min. For DAB staining, each 
section was treated with 0.3 % H2O2 for 5 min to inhibit endogenous peroxidase 
activity. The following antibodies were used: 4G8 for Aβ (Covance), MOAB-2 
for Aβ (Novus), NSE (Zymed), SYP (Santa Cruz), and Iba1 (Wako).  
 
Propagation of oAβ1-42 in microfluidic chamber 
Master mold was fabricated on the wafer using soft lithography technique as 
described (Park et al., 2006). PDMS base and curing agent (Dow Corning) were 
mixed thoroughly and solidified on the mold at 80ºC for 1 h. Resulting 
microfluidic chambers contain two compartments connected by 400 μm-length 
ippocampal neurons were plated into donor compartment at the density of 1.0 x 
106 cells/ml and recipient compartment at the density of 0.2 x 106 cells/ml. Cells 
in donor compartment at 3 days in vitro were incubated with 1 μM FITC-oAβ1-
42 when axons did not stretch into the opposite side yet for 24 h and then 
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incubated with Aβ1-42-free medium for 3 more days. At that point, axons from 
donor neurons traverse the microgrooves. Propagation of green signal 




All statistical analyses were performed with GraphPad Prism Software. 
Comparisons between two means were performed by unpaired two-tailed t test. 
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Amyloid-β1-42 (Aβ1-42) is a critical factor of neuronal cell death and is 
associated with the pathogenesis of Alzheimer’s disease (AD) (Hardy and 
Selkoe, 2002). The neurotoxic cascades initiated by extracellular Aβ1-42 are 
mediated by membrane receptors. Recently, FcγRIIb is identified to be 
implicated in Aβ1-42 neurotoxicity in vitro and memory impairment in AD model 
mice via interaction with Aβ1-42 (Kam et al., 2013). However, downstream 
events initiated by FcγRIIb in neuronal cells are unknown. Here, I show that 
Lyn contributes to Aβ1-42 and FcγRIIb-mediated neurotoxicity. I found that 
exposure of neuronal cells to Aβ1-42 activated Lyn and induced the 
phosphorylation of FcγRIIb at Tyr273. Interestingly, knockdown of Lyn 
expression with shRNA decreased the phosphorylation of FcγRIIb following 
Aβ1-42 exposure. In addition, down-regulation of Lyn also reduced neuronal cell 
death induced by Aβ1-42. From the virtual screening, I isolated a small molecule 
KICG2576, an ATP-competitive inhibitor of Lyn. KICG2576 bound to Lyn in 
the cleft between the two lobes of the kinase domain in determination of co-
crystal structure and inhibited Lyn activation. Consistently, KICG2576 inhibited 
Aβ- or FcγRIIb-induced neuronal cell death at sub-micromolar range. Further, 
intracerebroventricular-injection of KICG2675 into mice ameliorated Aβ-
induced memory impairment in Y-maze and novel object recognition tests. 
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These results suggest that Lyn plays an essential role in Aβ1-42–mediated 





Alzheimer’s disease (AD) is the most common form of dementia and represents 
impaired cognition and loss of memory (Hardy and Selkoe, 2002). Amyloid-
beta (Aβ) is the major component of senile plaque which is a remarkable 
hallmark in the brain of AD patients (O’Brien and Wong, 2010). Aβ1-42 is the 
proteolytic product composed of 42 amino acids from amyloid precursor protein 
(APP) and is self-aggregated to form stable fibril and plaque, eventually 
(Roychaudhuri et al., 2009). Aβ1-42 is considered as a key toxic mediator in AD, 
and some mutations in APP, which induce the overproduction of Aβ1-42, trigger 
familial type of AD (Bertram et al., 2010; Reinhard et al., 2005). Recently, 
soluble oligomeric forms of Aβ1-42 are regarded as potent species of toxicity 
(Haass and Selkoe, 2007). Several Aβ1-42 oligomer species derived from AD 
patient or AD mice model have been reported to mediate memory impairment 
and loss of long-term potentiation (LTP) (Lesne et al., 2006; Shankar et al., 2008; 
Walsh et al., 2002). However, the acting mode of Aβ1-42 oligomer on the 
pathogenesis of AD is unclear.  
Recently, immune inhibitory receptor FcγRIIb was validated to be a receptor 
of Aβ1-42 oligomer (Kam et al., 2013). Physical interaction between Aβ1-42 and 
FcγRIIb was largely increased in the brains of AD patients. FcγRIIb knockout 
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(KO) neuron is less vulnerable to Aβ1-42-induced neuronal death than wild-type 
(WT) neuron. In addition, genetic ablation of FcγRIIb in PDAPP mice reverses 
the cognitive deficit observed in these mice. Despite these effects, cellular 
mechanism caused by the interaction between Aβ1-42 and FcγRIIb is uncertain.  
FcγRIIb functions mainly in immune system, especially in B cell. Inhibitory 
signaling initiated by FcγRIIb is dependent on its immunoreceptor tyrosine-
based inhibitory motif (ITIM) located in the cytosolic region (Nimmerjahn and 
Ravetch, 2008). This phosphorylation serves as a binding site with SH2-
containing inositol phosphatase-1 (SHIP-1) (Ono et al., 1996). SHIP-1 blocks 
the recruitment of several pleckstrin homology (PH) domain-containing kinases, 
such as Btk and Akt, to plasma membrane, eventually leading to inhibition of 
calcium flux and proliferation of B cells (Carter et al., 1991; Jacob et al., 1999; 
Ono et al., 1996). Lyn, a member of Src-family tyrosine kinase (SFK), is focused 
on its role in the phosphorylation of several immune inhibitory receptors, 
including FcγRIIb (Xu et al., 2005). Importantly, Tyrosine phosphorylation of 
FcγRIIb within its ITIM was mostly reduced in B cells isolated from Lyn KO 
mice (Chan et al., 1998). Moreover, phenotype of Lyn KO mice is similar with 
that of FcγRIIb KO mice in that both of them succumb to autoimmune response 
(Bolland and Ravetch 2000; Hibbs et al., 1995). Thus, while the function of Lyn 
in FcγRIIb-mediated B cell inhibition is critical, its role in Aβ1-42–induced 
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neuropathology remains elusive.  
Here I show that Lyn plays an essential role in Aβ neurotoxicity in which 
Lyn is responsible for the phosphorylation at Tyr273 within ITIM of FcγRIIb. I 
isolated an inhibitor of Lyn (KICG2576) and found that KICG2576 attenuated 
Aβ1-42 and FcγRIIb-mediated neurotoxicity. Further, intracerebroventricular 
(i.c.v.)-administration of KICG2576 suppresses Aβ1-42-induced memory 
impairment. These findings suggest a neuronal role of Lyn in Aβ neurotoxicity 





Aβ1-42 stimulates Lyn kinase to phosphorylate FcγRIIb 
Since it is known that tyrosine 273 within FcγRIIb ITIM is phosphorylated by 
Lyn to inhibit B cell proliferation (Nimmerjahn and Ravetch, 2008), I attempted 
to identify whether Lyn was activated in neuronal cells by Aβ. Western blot 
analysis using phospho-specific antibody showed that treatment of Aβ1-42 to 
both primary cortical neurons and SH-SY5Y neuroblastoma cells enhanced the 
phosphorylation at tyrosine 397 (Figure II-1A), an activatory phosphorylation 
of Lyn (Hirao et al., 1997). The mode of Lyn activation by Aβ was dose-
dependent and maximal activity was acquired by over 2 μM (Figure II-1B). 
Unlike its dose-dependency, tracking the activity of Aβ1-42-stimulated Lyn by 
time-course revealed that Lyn was rapidly activated about tenfold and gradually 
lost its activity for over 36 hours (Figure II-1C).  
I also found that Aβ treatment increased the phosphorylation of FcγRIIb at 
tyrosine 273 in SH-SY5Y cells as well as the phosphorylation of Lyn at tyrosine 
397 (Figure II-2A). Thus, I assessed whether Lyn is responsible for the Aβ-
induced phosphorylation of FcγRIIb in neuronal cells. I reduced the level of Lyn 
expression using shRNA in SH-SY5Y cells (Figure II-2A). Unlike in control 
cells, Aβ1-42 treatment did not induce the activatory phosphorylation of FcγRIIb 
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at tyrosine 273 as well as that of Lyn in Lyn knockdown cells. In addition, 
increased association of Lyn with FcγRIIb triggered by Aβ1-42 is verified by 
immunoprecipitation assay (Figure II-2B). Conditioned media from Chinese 
hamster ovary cells which stably express Val717Phe mutation of APP751 (7PA2 
cells) were characterized to secrete soluble oligomer of Aβ1-42 (Podlisny et al., 
1998 and Walsh et al., 2002). Treatment of conditioned media from 7PA2 cells 
enhanced endogenous interaction between Lyn and FcγRIIb in SH-SY5Y cells. 
These results suggest that Lyn is required for the phosphorylation of FcγRIIb at 
tyrosine 273 in neuronal cells after exposure to Aβ1-42.  
 
Lyn is associated with Aβ1-42-evoked neuronal cell death 
Since tyrosine 273 in ITIM of FcγRIIb is phosphorylated by Aβ via Lyn and this 
region is important in FcγRIIb-mediated neuronal cell death, I attempted to 
discover the role of Lyn in Aβ1-42-evoked neuronal cell death. I utilized two 
neuronal cell lines, B103 rat neuroblastoma cells and HT22, which are 
vulnerable to Aβ1-42 to evaluate the cell death (Song et al., 2008). Compared to 
untreated control cells, Aβ1-42 treatment induced 45% of cell death in B103 cells. 
On the other hand, knockdown of Lyn expression effectively reduced the 
neuronal cell death to 27% (Figure II-3A). Amelioration of Aβ1-42-induced 
neuronal cell death by silencing Lyn expression was also observed in HT22 cells 
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(Figure II-3B). In both cases, both Lyn expression and Lyn phosphorylation at 
tyrosine 397 were reduced by expression of Lyn shRNA (Figure II-3). These 
results indicate that stimulation of Lyn contributes to Aβ neurotoxicity.  
 
Overall structure of Lyn kinase domain in complex with the inhibitor, 
KICG2576 
To provide a concept of Lyn inhibition in Aβ-neurotoxicity, I attempted to 
generate a novel Lyn inhibitor through virtual screening. The overall structure 
of Lyn kinase domain is similar to the structures of well known kinase proteins 
which contain two lobes such as N-lobe and C-lobe. As shown in Figure II-4A, 
the N-lobe consists of five anti-parallel β sheets and a regulatory αC helix. The 
C-lobe is predominantly α-helical and serves as a docking site for substrates. 
ATP-binding pocket lies at the interface between the N- and C-lobes (Figure II-
4A). Region of the activation loop (residues 392-400), including the 
phosphorylation residue Tyr397, is disordered and does not show a clear 
electron density. Western blot analysis showed that the purified Lyn kinase is 
unphosphorylated at Tyr397 in the activation loop. 
Based on this structure, I isolated small molecule, KICG2576, as a novel 
inhibitor of Lyn and identified the mode of interaction of them. KICG2576, an 
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ATP-competitive inhibitor, binds with the Lyn kinase in the cleft between the 
two lobes of the kinase domain (Figure II-4B). There are two hydrogen bonds 
identified between the inhibitor and the proteins. The aminoquinazoline moiety 
of KICG2576 makes two hydrogen bonds with backbone NH and carbonyl 
oxygen of Met322 in the hinge region. In addition to the hydrogen bonds, 
several hydrophobic interactions are found. The planar quinazoline and 
immidazole rings of KICG2576 are sandwiched between the hydrophobic 
residues of the N-lobe (Leu253, Val261, and Ala273), the hinge region (Phe321), 
and the C-lobe (Leu374). Furthermore, deep hydrophobic pocket is occupied by 
propyl moiety of the inhibitor, forming extensive van der Waals contacts with 
Glu290, Met294, A384, and T319. 
Next, I conducted in vitro kinase assay to confirm whether KICG2576 inhibits 
Lyn activity (Figure II-5A). In this assay, dephosphorylated casein served as an 
exogenous substrate for the immunoprecipitated Lyn (Young et al., 2003). 
Incubation of HT22 cells with KICG2576 diminished immunoreactivity against 
the phosphorylated α-casein compared to DMSO control or LynK-in#25, a 
negative-control small molecule which does not interact with Lyn. Enzymatic 
activity of Lyn was inhibited at 0.5 μM concentration of KICG2576. Then, I 
assessed the effects of KICG2576 on the phosphorylation of Lyn. Incubation of 
SH-SY5Y cells with 0.5 μM KICG2576 prevented Aβ1-42-induced 
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phosphorylation of Lyn at tyrosine 397 to control level (Figure II-5B). These 
results indicate that KICG2576 is a potent inhibitor of Lyn and inhibits Aβ1-42-
triggered Lyn activation.  
 
KICG2576 inhibits Aβ1-42- and FcγRIIb-induced neuronal cell death 
I then examined the effects of KICG2576 on Aβ1-42–induced neurotoxicity. 
Incubation of HT22 cells with 0.5 μM KICG2576 completely suppressed Aβ1-
42 neurotoxicity to control level (Figure II-6A). Aβ1-42–induced neurotoxicity 
was even significantly inhibited by 0.01 μM KICG2576, while LynK-in#25 did 
not affect on the cell death. Further, I compared KICG2576 to PP1, a widely 
used inhibitor of Src-family kinases including Lyn, with regard to 
neuroprotective effect against Aβ1-42 (Figure II-6B). Interestingly, effect of 
KICG2576 in rescuing Aβ1-42-neurotoxicity was better than that of PP1. While 
PP1 prevented Aβ1-42-cytotoxicity over 1 μM, neuroprotection against Aβ1-42 
was fulfilled by treatment of at least 0.1 μM KICG2576. Similarly, KICG2576 
exhibited an inhibitory activity against Aβ1-42–neurotoxicity in primary cortical 
neurons; 0.5 μM KICG2576 was most effective than 0.1 μM (Figure II-7). 
Western blot analysis also revealed that KICG2576 inhibited proteolytic 
activation of caspase-3 in a dose-dependent manner as well as activatory 
phosphorylation of Lyn (Figure II-7). However, KICG2576 did not affect cell 
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death induced by other insults, including TNF-α and etoposide in HT22 cells 
(Figure II-8).  
Since FcγRIIb is a key mediator of Aβ1-42–mediated cell death and Lyn 
phosphorylates FcγRIIb under Aβ1-42 stimulus, I investigated the ability of 
KICG2576 to affect FcγRIIb-mediated cell death. Consistently, KICG2576 
inhibited cell death elicited by ectopic expression of FcγRIIb in HT22 cells 
(Figure II-9A). In addition, KICG2576 also inhibited the phosphorylation of 
FcγRIIb at tyrosine 273 (Figure II-9B). All these results are consistent with our 
earlier observation showing the role of Lyn in Aβ1-42- and FcγRIIb-mediated cell 
death. Thus, it appears that KICG2576 abrogates Aβ1-42 neurotoxicity by 
prohibiting Lyn. 
 
KICG2576 rescues memory impairment triggered by i.c.v. injection of Aβ1-
42 
Because Aβ neurotoxicity provides cellular basis for memory deficits and 
neuropathological features of dementia in AD (Haass and Selkoe, 2007 and 
Selkoe, 2002), I investigated effect of KICG2576 on learning and memory 
deficits in mice using intracerebroventricular(i.c.v.) injection model of Aβ1-42. I 
found that spatial memory measured with Y maze test was impaired for 10 days 
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in Aβ1-42-injected mice (Figure II-10A). On the other hand, co-injection of 
KICG2576 with Aβ1-42 rescued the memory impairment. The decline of 
spontaneous alteration was completely restored at 22 day after injection (Figure 
II-10B). In addition, objective memory measured with novel object recognition 
task was impaired by Aβ1-42 injection but discrimination of the novel object from 
familiar object was obtained by co-injection of KICG2576 (Figure II-10C). 
These results indicate that KICG2576 can rescue the memory impairment 
induced by Aβ1-42 injection in mice.  
 
Lyn is activated in the brain of AD patients 
In order to examine in vivo relevance of Lyn, I analyzed the kinase activity of 
Lyn in the brain extracts of normal individuals and AD patients. Interestingly, I 
found that, the activatory phosphorylation of Lyn was increased in AD patients 
compared to healthy controls, whereas there was no significant change in the 
level of total Lyn (Figure II-11). In summary, I confirmed the pathologic 




Figure II-1. Lyn is activated by Aβ1-42 oligomer in neuronal cells.  
(A) Phosphorylation of Lyn at Tyr397 by Aβ1-42. Primary cortical neurons (DIV 
5) and SH-SY5Y neuroblastoma cells were treated with PBS or 5 μM Aβ1-42 
oligomer for 24 h. Cell lysates were prepared and subjected to western blotting 
with the phospho-Lyn tyrosine 397 (Y397) antibody. (B and C) Increase of Lyn 
phosphorylation at Tyr397 by Aβ1-42 in a dose- and time-dependent manner. SH-
SY5Y cells were treated with PBS or the indicated concentrations of Aβ1-42 for 
12 h (B) or 2 μM Aβ1-42 for the indicated times (C). Cell lysates were 
immunoblotted with phospho-Lyn tyrosine 397 (Y397) antibody. Graphs 
represent the relative ratios of p-Lyn (Y397) levels to Lyn in upper panels with 







Figure II-2. Lyn is required for the phosphorylation and activation of 
FcγRIIb by Aβ1-42.  
(A) Abrogation of Aβ1-42-induced phosphorylation of FcγRIIb by Lyn 
knockdown. SH-SY5Y cells were transfected with pSUPER-neo (Mock) or 
pLyn shRNA (shLyn) for 48 h and then incubated with PBS or 2 μM Aβ1-42 for 
additional 12 h. Cell lysates were immunoblotted using p-FcγRIIb, FcγRIIb, p-
Lyn (Y397), Lyn and β-actin antibodies. (B) Enhanced interaction between Lyn 
and FcγRIIb owing to Aβ1-42. SH-SY5Y cells were treated with conditioned 
medium of either CHO cell or 7PA2 cell, stably expressing APP V717F mutant, 
for 24 h. Cell lysates were subjected to immunoprecipitation assay with normal 
mouse IgG (IgG) or Lyn antibody (Lyn). The immunoprecipitates were then 






Figure II-3. Reduced expression of Lyn suppresses Aβ1-42-induced neuronal 
cell death.  
Inhibition of Aβ1-42-induced cell death by silencing Lyn expression. B103 cells 
(A) and HT22 cells (B) were transfected with pSUPER-neo (Mock) or pLyn 
shRNA (shLyn) for 24 h and then exposed to PBS or 5 μM Aβ1-42 for 36 h. Cells 
which had apoptotic fragmented nuclei characterized by EtHD were considered 
as dead cells (left). Bars represent mean ± SD (n = 3). Cell extracts were 
prepared and immunoblotted with p-Lyn (Y397), Lyn and β-actin antibodies 








Figure II-4. Co-crystal structure of kinase domain of Lyn with KICG2576.  
(A) Ribbon representation of the crystal structure of Lyn kinase domain. The N- 
and C-lobes are colored in green and cyan, respectively. The hinge region is 
colored in yellow and the activation loop in orange. (B) Hydrogen and 
hydrophobic interactions between the inhibitor KICG2576 and Lyn kinase 
















Figure II-5. Effective inhibition of Lyn by KICG2576.  
(A) In vitro kinase assay showing dose-dependent inhibition of Lyn kinase 
activity by KICG2576. HT22 cells were treated with DMSO or the indicated 
concentrations of KICG2576 or LynK-in#25 (#25, negative control) for 24 h. 
Cell lysates were subjected to immunoprecipitation assay with pre-immune 
serum (Pre) or Lyn antibody (Lyn). The immunoprecipitates were incubated 
with dephosphorylated casein and the reaction mixtures were immunoblotted 
with p-Tyr (Top, short and long) and Lyn antibodies (middle). Casein was 
stained with Coomassie (bottom). (B) Inhibition of Aβ1-42-induced auto-
phosphorylation at tyrosine 397 of Lyn by KICG2576. SH-SY5Y cells were pre-
treated with DMSO or 0.5 μM KICG2576 for 2 h and then incubated with PBS 
or 5 μM Aβ1-42 for 12 h. Cell extracts were immunoblottted with p-Lyn (Y397), 









Figure II-6. Suppression of Aβ1-42-evoked cell death by KICG2576.  
(A) Protection of Aβ-triggered cell death by KICG2576. HT22 cells were pre-
treated with the indicated concentrations of each compound (KICG2576 and 
#25: LynK-in#25) for 2 h and then exposed to DMSO or 5 μM Aβ1-42 for 36 h 
in the presence of those molecules. Cell death was measured by trypan blue 
exclusion assay. Bars represent mean ± SD (n = 3). (B) Comparison of 
KICG2576 to PP1 in aspect with their protective ability against Aβ1-42. HT22 
cells were pre-treated with the indicated concentrations of pyrazolopyrimidine1 
(PP1) and KICG2576 for 2 h and then exposed to DMSO or 5 μM Aβ1-42 for 36 
h in the presence of those molecules. Cell death was assessed as in (A). Bars 
represent mean ± SD (n = 3). #P < 0.005 versus PBS with DMSO-treated sample 
(PBS). **P < 0.005, ***P < 0.0005 versus Aβ1-42 with DMSO-treated sample 







Figure II-7. Suppression of Aβ1-42-induced neuronal death by KICG2576.  
Primary cortical neurons at DIV 5 were pre-treated with DMSO or the indicated 
concentrations of each compounds (KICG2576 and #25: LynK-in#25) for 2 h 
and then incubated with 5 μM Aβ1-42 for 48 h. Cell death was assessed by trypan 
blue exclusion assay. Results represent mean ± SD (n=3) (Left). #P < 0.005 
versus PBS with DMSO-treated sample (PBS). *P < 0.05, **P < 0.005 versus 
Aβ1-42 with DMSO-treated sample (DMSO). Cell lysates were immunoblotted 








Figure II-8. KICG2576 does not affect apoptosis triggered by TNF-α or 
etoposide.  
HT22 cells were treated with DMSO or 0.5 μM KICG2576 for 2 h and then 
incubated with 30 ng/ml TNF-α with 10 μg/ml cyclohexamide (CHX) for 6 h or 








Figure II-9. Suppression of FcγRIIb-induced cytotoxic signaling by 
KICG2576.  
(A) Inhibition of FcγRIIb-mediated cell death by KICG2576. HT22 cells were 
incubated with DMSO, 0.5 μM KICG2576 or LynK-in#25 (#25) and transfected 
with pEGFP-N1 (Mock) or pFcγRIIb-EGFP (FcγRIIb) for 36 h. Cells with 
apoptotic fragmented nuclei characterized by EtHD were considered as dead 
cells. Results represent mean ± SD (n = 3). **P < 0.005. (B) Suppression of 
FcγRIIb tyrosine phosphorylation at ITIM by KICG2576. SH-SY5Y cells were 
pre-treated with the indicated concentrations of KICG2576 or LynK-in#25 for 
2 h and transfected with pFcγRIIb-EGFP for additional 24 h. Cell lysates were 










Figure II-10. KICG2576 prevents intracerebroventricularly injected Aβ1-
42-induced behavioral alteration. 
(A-C) Memory defects initiated by i.c.v. Aβ1-42 was suppressed by KICG2576 
in mice. WT mice (5-week-old; 3-6 mice per group) were i.c.v.-injected with 
PBS or Aβ1-42 (410 pm) alone or together with KICG2576 (molar ratio with 1:3). 
After two and ten days, spatial memory of mice was analyzed using Y-maze test. 
Graphs represent the reversible memory impairment of i.c.v. Aβ1-42-injected 
mice after 22 days in Y-maze test (B). Object recognition memory was reflected 
by the percentage of time that each group of mice spent exploring a familiar 
versus a novel object (C). Values represent mean ± SEM of all independent 









Figure II-11. Lyn is activated in the hippocampus of AD patients.  
(A) Activation of Lyn in the hippocampus of AD patients. Hippocampal lysates 
from normal individuals and AD patients were immunoblotted using p-Lyn 
(Y397), Lyn and β-actin antibodies. (B) Graph depicts the densitometric 









Figure II-12. KICG2576 modulates expression of inflammatory cytokines 
by Aβ1-42 in BV-2 microglial cells.  
BV-2 cells were pre-incubated with DMSO or 0.5 μM KICG2576 (2576) for 4 
h and then treated with 2 μM Aβ1-42 or 1 μg/ml lipopolysaccharide (LPS) for 6 
h. Cell lysates were prepared and subjected to RT-PCR analysis using synthetic 







Table II-1. Crystallographic data collection and refinement statistics of 










Though signaling cascades mediated by tyrosine kinase have been studied for 
a long time, their contribution in the pathogenesis of AD is not clear. However, 
their role is thought to be critical in AD pathogenesis in that several tyrosine 
kinase inhibitors, including Gleevec and STI571, have been reported to be 
beneficial to AD pathology (Cancino et al., 2008; Dhawan et al., 2012; 
Lonskaya et al., 2013; Netzer et al., 2003). Here I report that Lyn, a member of 
SFK, is involved in the pathogenesis of AD by regulating Aβ1-42-FcγRIIb 
pathway.  
Although several receptors about Aβ1-42 such as receptor for advanced 
glycosylation end products (RAGE) and cellular prion protein (PRNP) have 
been isolated and their contributions to Aβ1-42-neurotoxicity are well-established, 
there are no therapeutic approaches using molecular targets based on their 
downstream pathway (Lauren et al., 2009; Yan et al., 1996). Moreover, 
limitation of RAGE inhibition for AD therapy confirmed by ineffective result 
of clinical trial about PF-04494700, an oral inhibitor of RAGE, suggests the 
need for novel targets of drug development (Sabbagh et al., 2011). Even though 
KICG2576 has much room for improvement about accessibility across blood-
brain barrier (BBB) and selectivity, our data imply that blockade of Aβ1-42-
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FcγRIIb signaling through Lyn inhibition can be a good alternative for the 
attempt to AD therapeutics.  
While Lyn is known to mediate signaling cascades initiated by several 
immunoreceptors and inflammation signal in immune cells, increasing 
evidences suggest that Lyn also plays a crucial role in neuroinflammation which 
is an important feature of AD pathology. In the brain, Lyn delivers Aβ1-42-
initiated inflammatory signaling in microglia and activates NF-κB pathway to 
produce cytokines, leading to exacerbate the symptoms of AD (Querfurth and 
LaFerla, 2010; Stewart et al., 2010). Consistently, I also confirmed that 
induction of inflammatory cytokines by Aβ1-42 was reduced under treatment of 
KICG2576 in BV-2 microglia cells (Figure II-12). Moreover, I first identified 
the neural role of Lyn in neurodegenerative disease in this study. Though I 
concentrated the effect of Aβ1-42-induced Lyn activation in aspect of neuronal 
death, there are enough possibilities of relevance of Lyn to other neuronal 
malfunctions involved in AD. Follow-up studies about the specific events 
encouraged by Lyn activation will provide an elaborated view of 
neurodegenerative mechanisms.  
Fyn, a member of SFK, is highly homologous to Lyn and much of its function 
overlaps with Lyn in that functional complementation is attained by Fyn in Lyn-
deficient mice (Odom et al., 2004). Recent study shows that Fyn is required for 
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Aβ1-42 neurotoxicity mainly through the excitotoxicity mediated by NMDA 
receptor (Um et al., 2012). Because all members of SFK share common 
regulatory mechanism which determines the phosphorylation status of C-
terminal regulatory domain, it is plausible that both Lyn and Fyn are activated 
by Aβ1-42. In contrast to complementary function in immune cells, however, it 
appears that Fyn and Lyn are differently activated during Aβ1-42 toxicity in 
neuronal cells. Fyn is transiently activated within 1 h after Aβ1-42 treatment, 
whereas the activation of Lyn lasts for 36 h (Um et al., 2012). Considering that 
the expression and phosphorylation of FcγRIIb are induced by Aβ1-42 for more 
than 24 h in neuronal cells (Kam et al., 2013), the prolonged activation of Lyn 
may potentiate Aβ1-42 neurotoxicity through FcγRIIb. 
Since kinase domains of individual SFK family members are highly conserved, 
it is difficult to develop a selective inhibitor of them. Actually, PP1 and PP2, 
other commercial inhibitors of SFK, prohibit not only Lyn but also all SFKs at 
the concentration over 10 μM (Summy et al., 2005). However, both compounds 
have some “off-target” kinases at these concentrations. In this study, I 
characterized KICG2576, a highly efficient inhibitor of Lyn by combining 
structure-based drug design and high-throughput screening (HTS). Fortunately, 
I discovered that KICG2576 effectively inhibits Aβ1-42-neurotoxicity at sub-
micromolar concentrations on the contrary to PP1 (Figure II-6B). High 
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efficiency of KICG2576 in low concentration is advantageous in that non-
selective inhibition of other kinases like p38 and MEK1 provoked by 
micromolar usage of PP1 can be avoided (Bain et al., 2003). However, I cannot 
exclude the cross-reactivity of KICG2576 with other SFKs. Thus, it is required 
to further develop more specific Lyn inhibitor, though this study shows that Lyn 
is required for Aβ1-42-neurotoxicity in vitro and in vivo, and provide a potential 
of new target for drug development,  
I isolated KICG2576 as a novel inhibitor of Lyn. KICG2576 effectively 
inhibits Lyn activity in vitro and in cells. However, KICG2576 exhibits low 
accessibility of BBB. That is why I tried to analyze the effect of KICG2576 on 
Aβ1-42-neurotoxicity in vivo using i.c.v. injection assay as the second best try. 
Because I found positive effect of brain-injected KICG2576 in several behavior 
tests, it is necessary to characterize derivatives of KICG2576 which exhibit 
more hydrophobicity and lower molecular weight to acquire improved BBB 
entrance.  
In conclusion, I demonstrate that Lyn is implicated in the pathogenesis of AD 
by mediating Aβ1-42-FcγRIIb signaling. In addition, I provide insight of Lyn 




Materials and methods 
Reagents 
Synthetic human Aβ1-42 peptide (Sigma-Aldrich®, MO, U.S.A.), 
dephosphorylated casein (Sigma-Aldrich®), PP1 (Calbiochem®, Darmstadt, 




The cDNA of human FcγRIIb variant 2 was subcloned into pEGFP-N1 
(Clontech, CA, U.S.A.) (pFcγRIIb-EGFP). FcγRIIb-ΔC, ΔITIM, and ΔCyto 
deletion mutants were generated by PCR and the PCR products were inserted 
into pEGFP-N1 (pFcγRIIb ΔC-EGFP, pFcγRIIb ΔITIM-EGFP, and pFcγRIIb 
ΔCtyo-EGFP, respectively). FcγRIIb Y273F mutant was generated by site-
directed mutagenesis. To make shRNA construct of Lyn (pLyn shRNA), 
oligonucleotides containing gene-specific sequences (5′- GGG AAG TCT GGA 
TGG GTT A-3′) were annealed and ligated into BglII and HindIII sites of 
pSUPER.neo (OligoEngine, WA, U.S.A.). The C-terminal segment (human Lyn 
kinase, residues 239–512) containing the kinase domain was inserted into 




Preparation of Aβ1-42 
Synthetic human Aβ1-42 peptide was dissolved in DMSO at 2.2 mM and further 
diluted in PBS at 250 μM. Diluted Aβ1-42 was incubated at 4 °C for 48 h and 
then stored at -70 °C until use. Naturally secreted Aβ1-42 was acquired as 
described (Kam et al., 2013). Briefly, Chinese hamster ovary cells stably 
expressing human APP751 with Val717Phe mutation, provided kindly by Dr. D. 
J. Selkoe (Harvard Medical School), were grown to approximately ~90 % 
confluence. Then, cells were washed with PBS and further cultured for ~16 h in 
serum-free DMEM. The conditioned media were collected and centrifugated at 
1000 g to remove cell debris. Supernatants were concentrated ~10-fold using 
YM-3 Centriprep filters (Millipore).  
 
Cell culture and DNA transfection 
B103 rat neuroblastoma cells, HT22 mouse hippocampal cells, SH-SY5Y 
human neuroblastoma cells, CHO Chinese hamster ovary cells, and BV-2 mouse 
microglial cells were cultured in Dulbecco’s modified eagle medium (DMEM; 
Hyclone®, UT, U.S.A.) replenished with 10 % (v/v) fetal bovine serum (FBS; 
Hyclone®). Mouse cortical primary neurons were cultured as described 
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previously (Park et al., 2012). Briefly, mouse brain cortical tissue from 
embryonic day 16 was isolated and triturated using Trypsin-EDTA (Gibco®, NY, 
U.S.A.). Cortical neurons were placed on the poly-L-Lysine (Sigma-Aldrich®)-
coated culture plates and maintained in Neurobasal medium (Gibco®) 
supplemented with 2 % B-27 (Invitrogen™, CA, U.S.A.) and 0.5 mM L-
glutamine (Invitrogen™). B103, HT22, and SH-SY5Y cells were transfected 
with appropriate DNA using Polyfect reagent (Qiagen, CA, U.S.A.) according 
to the manufacturer’s protocol.  
 
Reverse transcription-PCR 
Total RNAs were purified from Aβ1-42 or LPS-stimulated BV-2 cells using TRI 
reagent® (MRC Inc., OH, U.S.A.) according to the manufacturer’s instruction. 
Cytokine RNAs were identified by PCR with cytokine-specific synthetic 
primers after synthesis of cDNA with M-MLV reverse transcriptase 
(Enzynomics™, Daejeon, South Korea). The sequences used for PCR are as 
follows; MCP-1, sense 5’- CCT GCT GTT CAC AGT TGC C - 3’, and antisense 
5′-TGA GGT GGT TGT GGA AAA GG-3′; TNF-α, sense 5′-TTC TGT CTA 
CTG AAC TTC GGG GTG ATC GGT CC-3′, and antisense 5′-GTA TGA GAT 
AGC AAA TCG GCT GAC GGT GTG GG -3′; CD11b, sense 5′-CAG ATC 
AAC AAT GTG ACC GTA TGG G-3′, and antisense 5′-CAT CAT GTC CTT 
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GTA CTG CCG CTT G-3′; β-actin, sense 5′-ATG GGG AAG GTG AAG GTC 
GGA-3′, and antisense 5′-CCA TGA CGA ACA TGG GGG CAT-3′.  
 
Western blotting and antibodies 
The following antibodies were used for western blot analysis; p-Lyn (1645-5), 
and p-FcγRIIb (2308-1) (Epitomics, Inc. CA, U.S.A.), Lyn (sc-15), GFP (sc-
8334), and β-actin (sc-47778) (Santa Cruz biotechnology, CA, U.S.A.), FcγRIIb 
(ab45143: Abcam, MA, U.S.A.), and cleaved caspase-3 (#9661, Cell signaling, 
MA, U.S.A.). Generally, cell extracts were dissolved with ice-cold RIPA buffer 
[50 mM Tris-Cl pH 7.5, 30 mM NaCl, 1 % Triton-X100, 0.5 % sodium 
deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 1 mM Na3VO4]. After brief 
centrifugation, the supernatant was subjected to SDS-polyacrylamide gel 
electrophoresis (PAGE), and transferred to polyvinylidene fluoride (PVDF) 
membrane using Semi-Dry transfer cell (Bio-Rad, CA, U.S.A.). Blots were 
blocked by 3 % (w/v) BSA solution in TBS-T [10 mM Tris-Cl pH 8.0, 150 mM 
NaCl, 0.5 % (v/v) Tween-20] and subjected to western blot analysis. 





SH-SY5Y cells were lysed with 0.5X RIPA buffer (25 mM Tris-Cl pH 7.5, 15 
mM NaCl, 0.5 % Triton-X100, 0.25 % sodium deoxycholate, 0.05 % SDS, 1 
mM PMSF, and 1 mM Na3VO4). After centrifugation at 12000rpm, the 
supernatant was incubated with 2 μg of mouse normal IgG or Lyn antibody (sc-
15) for overnight at 4 °C. After adding 30 μl protein G bead (GE Healthcare), 
mixtures were incubated for additional 2 h at 4 °C. Proteins bound to Protein G 
bead were pulled down by centrifugation after three times of washes and 
analyzed by western blotting.   
 
Cell death assessment 
Cell death rates were determined as described previously (Oh et al., 2012), In 
brief, cells were exposed to various stimuli and cell death was assessed by 
counting cells showing apoptotic fractured nucleic characterized by ethidium 
homodimer-1 (Molecular Probes, OR, USA) under a fluorescence microscope 
(Olympus, Tokyo, Japan). In other way, dead cells were counted after staining 
with 2 % trypan blue under a microscope.  
 
In vitro kinase assay 
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In vitro kinase assay of Lyn was conducted as depicted previously (Young et al., 
2003). Briefly, HT22 cells were solubilized with 0.5 X RIPA buffer. After 
centrifugation at 12000rpm, the supernatant was subjected to 
immunoprecipitation assay using pre-immune serum or Lyn antibody (sc-15). 
The immunoprecipitates were then mixed with dephosphorylated casein (1 
μg/μl) in kinase assay buffer (20 mM Tris-Cl pH 7.5, 10 mM MgCl2, 1 mM ATP, 
1 mM Na3VO4) and incubated for 15 min at 30 °C. Reaction was quenched by 
adding 5X non-reducing SDS sample buffer [60 mM Tris-Cl pH 7.5, 2 % SDS, 
25 % (v/v) glycerol] and mixtures were subjected to SDS-PAGE. The blots were 
analyzed with western blotting using p-Tyr (PY69, Santa Cruz biotechnology) 
and Lyn (sc-15) antibodies or stained with coomassie blue for casein.  
 
Protein expression and purification of Lyn kinase domain 
DH10Bac competent cells were transformed with the pFastBacHTa-hLyn to 
prepare the recombinant bacmid according to the instruction for Bac-to-Bac 
baculovirus expression systems (InvitrogenTM). Sf21 (Spodoptera frugiperda) 
insect cells were transfected with the recombinant bacmid containing 
pFastBacHTa-hLyn using Cellfectin reagent (InvitrogenTM) in medium A 
(Grace’s insect cell culture medium, TNM-FH and antibiotic–antimycotic 
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reagent). The insect cells were grown at 27.5 °C and the baculovirus were 
harvested at 72 h after transfection. For protein production, High Five 
(Trichopulsia ni) insect cells were infected with baculovirus, incubated in 
medium B (HyClone® SFX-Insect MP and antibiotic–antimycotic reagent) for 
48 h at 27.5 °C, harvested by centrifugation, and then frozen at -70 °C until 
purification. 
Purification was carried out at 4 °C unless otherwise stated and details of 
purification are described as follows. Frozen cells were thawed and suspended 
in buffer A [50 mM Tris-HCl pH 7.5, 5 % (v/v) glycerol, 200 mM NaCl, 2 mM 
DTT] containing 1 mM PMSF and complete protease inhibitors mixture (Roche 
Applied Sciences). Cells were disrupted by sonication and then cell lysate was 
then centrifuged at 35,000g for 1 h. The supernatant was filtered and loaded on 
a 5 ml Ni-NTA column (Histrap HP, GE healthcare) pre-equilibrated with buffer 
A. After washing the column with buffer A and again with the buffer A 
containing 20 mM imidazole, proteins were eluted with buffer A containing 
linear gradient of imidazole (20-500 mM). Lyn-containing fractions were 
pooled and treated with TEV protease overnight to cleave the His6 tag. Lyn 
kinase proteins were concentrated to 5ml and loaded on a gel filtration column 
(HiLoad 16/60 Superdex 75 prep grade, GE healthcare) pre-equilibrated with 
buffer B (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM DTT). Lyn-containing 
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fractions were pooled and loaded on anion-exchange column (Mono Q, GE 
Healthcare) followed by elution with a linear gradient of 500 mM NaCl in buffer 
C. Purified Lyn proteins were concentrated to 9 mg/ml for crystallization. 
 
Crystallization and data collection 
Lyn kinase protein (1 μl) was mixed with same volume of reservoir solution (23% 
PEG3350, 0.1 M NaCl and 0.1 M HEPES pH 7.5). Apo crystals of Lyn kinase 
domain were grown at 4 °C by vapor diffusion using the hanging-drop method. 
The complex crystals of the proteins with inhibitors were obtained by soaking 
the apo crystals in the reservoir solution with 1 mM inhibitor solution for 24 h. 
Prior to X-ray data collection, the crystals were transferred to the cryoprotectant 
solution for a few seconds and frozen in a stream of liquid nitrogen at 100K. 
The X-ray diffraction data was collected at 4A beam line of Pohang Light 
Source (PLS) and processed and scaled using HKL2000 (Otwinowski and 
Minor, 1997). A diffraction data of a crystal belongs to the rhombohedral space 
group R3 with one molecule per asymmetric unit.  
 
Structure determination and refinement 
The structure of Lyn was solved by molecular replacement using kinase domain 
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of Lyn (PDB code: 2ZV7) as an initial model. Refinement of the structure was 
carried out with the program CNS (Brunger et al., 1998) and manual model 
building was performed using the program QUANTA [Accelrys, Inc (San Diego, 
USA)]. Subsequent rounds of model adjustment, simulated annealing, and 
thermal parameter refinement were performed. A Fo-Fc electron density 
corresponding to the inhibitor was shown clearly after a full domain model of 
Lyn was built. Position of the inhibitor was determined based on Fo-Fc map. 
Quality of the refined structure was validated by using PROCHECK (Laskowski 
et al., 1993). Crystallographic data collection and refinement statistics are 
summarized in Table II-1.  
 
Intracerebroventricular (i.c.v) injection of Aβ1-42 and behavior tests 
Intracerebroventricular injection of Aβ1-42 and Y-maze task were performed as 
described previously (Yan et al., 2004). Novel object recognition task was 
examined as described (Tang et al., 1999). Aβ1-42 (2 μg) was administrated into 
i.c.v. region of 5-week-old mouse using Hamilton microliter #702 syringe 
(Hamilton, NV, U.S.A.) equipped with 26-gauge needle. These tests were 
accomplished in accordance with the regulations of the Animal Care and Use 





Data are expressed as mean ± SD or SEM as indicated. Differences between two 
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아밀로이드 베타는 알츠하이머병의 병리적 특징인 세포외 노인성 
플라크의 주 성분이며 다양한 경로를 통하여 신경세포에 독성을 
야기한다. 몇몇 막 단백질이 아밀로이드 베타에 결합하여 
신경독성회로를 유도하는 수용체로써 보고되어 왔다. FcγRIIb 는 
아밀로이드 베타 올리고머의 수용체로써 작용한다. FcγRIIb 의 
유전적 제거를 통하여 아밀로이드 베타 올리고머에 의해 유도되는 
신경세포 사멸과 LTP 저하가 감소되며 PDAPP 알츠하이머병 생쥐 
모델에서의 기억 감소 역시 복구시킨다. 최근에는 아밀로이드 베타- 
FcγRIIb 결합을 통한 Phosphoinositide 대사 변화가 타우 단백질의 
과인산화와 3x Tg-알츠하이머병 생쥐 모델에서의 기억 감소에 
기능한다고 보고되었다. 본 연구에서는 아밀로이드 베타의 신경내 
유입을 통한 FcγRIIb 의 새로운 병리적 기능을 밝혔다. 또한 
FcγRIIb 의 인산화를 야기하는 Lyn 의 역할 및 가상 스크리닝을 통해 
발굴한 잠재적 Lyn 저해제의 효과를 제시하였다.  
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세포내 아밀로이드 베타는 초기 알츠하이머병 환자의 뇌에서 
발견된다. 세포내 아밀로이드 베타를 보이는 몇몇 알츠하이머병 
생쥐 모델에서는 심지어 세포외 아밀로이드 침전이 없음에도 기억 
감소를 보이기도 한다. 나아가 병리적 아밀로이드 베타의 
신경세포간 전파가 신경세포내의 아밀로이드 베타의 축적과 
연관되어 있다. 하지만 신경세포내 아밀로이드 베타의 축적과 
인접한 신경세포로의 전파에 연관된 분자적 기작은 밝혀지지 
않았다. 본 논문의 첫 장에서는 FcγRIIb2 이형이 병리적 아밀로이드 
베타의 신경세포내 유입 및 신경세포간 전파에 작용하는 기능을 
밝혔다. 아밀로이드 베타 올리고머의 신경세포내 유입이 야생형 
생쥐의 신경세포에 비해 FcγRIIb 녹아웃 생쥐의 신경세포에서 
감소되어 있다. 3x Tg-알츠하이머 병 생쥐 모델에서의 신경세포내 
아밀로이드 베타 및 수용성 아밀로이드 베타가 FcγRIIb의 기능 
제거에 의해 감소되었다. 나아가 FcγRIIb의 아밀로이드 베타 유입이 
불가능한 돌연변이체를 전뇌특이적으로 발현하였을 때 3x Tg-
알츠하이머 병 생쥐 모델에서의 기억 감소가 완화되었다. 
신경세포에서 FcγRIIb 전사 이형 2 (FcγRIIb2)의 증대된 발현이 
아밀로이드 베타의 유입에 연관되어 있다. 기능성 스크리닝을 통해 
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동정한 TOM1은 FcγRIIb2에 결합하며 FcγRIIb2에 의한 아밀로이드 
베타의 유입을 저해한다. FcγRIIb2를 통한 FcγRIIb의 유입 가속화는 
세포질 및 미토콘드리아에서의 아밀로이드 베타를 축적시키며 신경 
독성을 야기한다. 마지막으로 서로 연결된 신경세포간의 아밀로이드 
베타의 전파가 FcγRIIb2의 제거를 통해 저해됨을 미세역학 기구를 
통하여 확인하였다. 이는 세포내 아밀로이드 베타를 조절함으로써 
알츠하이머병의 발병에 기능하는 FcγRIIb2 전사 이형의 새로운 
기능을 밝힌 것이다.  
Lyn은 Src-연관 타이로신 인산화 효소 중 하나로 밝혀졌으며 
FcγRIIb를 포함하는 면역 복합체에 결합하는 단백질을 
인산화함으로써 면역세포를 저해하는 기능이 보고되었다. 하지만 
신경세포에서의 아밀로이드 베타-FcγRIIb 신호체계에서의 연관성은 
밝혀지지 않았다. 본 논문의 두 번째 장에서는 Lyn이 FcγRIIb 를 
인산화함으로써 아밀로이드 베타에 의한 신경 독성 과정 중에서 
기능함을 밝혔다. 아밀로이드 베타 올리고머에 의해 Lyn이 
활성화되며 나아가 FcγRIIb 의 타이로신 인산화가 이루어진다. 
아밀로이드 베타에 의한 FcγRIIb의 인산화와 신경세포 독성은 Lyn의 
감소를 통하여 저해된다. ATP 경쟁적으로 작용하는 Lyn의 잠재적 
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저해제로써 저분자물질인 KICG2576을 가상 스크리닝을 통하여 
동정하였다. Lyn의 인산화효소 도메인의 두 엽 사이의 틈과 
KICG2576간의 결합을 공결정 구조를 통하여 확인하였다. 
아밀로이드 베타에 의한 FcγRIIb 의 인산화가 KICG2576에 의하여 
감소되는 동시에 아밀로이드 베타와 FcγRIIb 에 의한 신경세포 사멸 
역시 KICG2576을 통하여 완화되었다. 아밀로이드 베타의 주입에 
의한 기억 감소가 KICG2576의 뇌실내 주입을 통하여 개선되었음을 
Y자형 미로와 신규물체인식 실험을 통해 확인하였다. 마지막으로 
Lyn의 활성이 알츠하이머병 환자의 뇌에서 증가되어 있음을 
확인하였다. 정리하자면, Lyn은 아밀로이드 베타에 의한 신경 독성 
과정에서 기능하며 본 연구를 통해 알츠하이머병의 발병 과정에서 
아밀로이드 베타- FcγRIIb 신경 독성 체계에 대한 이해를 넓힐 수 
있었다.  
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